

Open Access Review



Unlocking nature's pharmacy: an in-depth exploration of phytochemicals as potential sources of anti-cancer and anti-inflammatory molecules

Shifana C. Sadiq^{1,2†}, Maria Pellissery Joy^{2†}, Sreekumar U. Aiswarya², Abhishek Ajmani¹, Chenicheri K. Keerthana², Tennyson P. Rayginia^{1,2}, Noah Isakov³, Ruby John Anto^{1,2,4*}


Academic Editor: Aamer Saeed, Quaid-I-Azam University, Pakistan

Received: May 21, 2024 Accepted: August 5, 2024 Published: October 30, 2024

Cite this article: Sadiq SC, Joy MP, Aiswarya SU, Ajmani A, Keerthana CK, Rayginia TP, et al. Unlocking nature's pharmacy: an in-depth exploration of phytochemicals as potential sources of anti-cancer and anti-inflammatory molecules. Explor Drug Sci. 2024;2:744–84. https://doi.org/10.37349/eds.2024.00073

Abstract

Phytochemicals, the bioactive compounds derived from plants, play a significant role in modulating pathways leading to cancer and inflammation, rendering themselves promising candidates for therapeutic interventions. This review explores the multifaceted potential of various phytochemicals in modulating key mechanisms involved in the development and progression of cancer and inflammation. The diverse array of phytochemicals discussed here encompasses polyphenols, flavonoids, alkaloids, terpenoids, and many others, each with distinct molecular targets and modes of action. This review is an attempt to elucidate and correlate the regulatory role of phytochemicals on cellular signaling pathways implicated in oncogenesis and inflammatory responses, highlighting the significance and potential of phytochemical-based therapies for cancer prevention and treatment, as well as for managing inflammatory conditions. By exploring the promising potential of phytochemical-based remedies for cancer prevention, treatment, and inflammatory conditions and emphasizing their diverse roles in modulating critical regulatory mechanisms, this review addresses the current research landscape, challenges, and future directions in utilizing phytochemicals as effective agents against cancer and inflammation.





¹Molecular Bioassay Laboratory, Institute of Advanced Virology, Thiruvananthapuram 695317, Kerala, India


²Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, Kerala, India

³The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel

⁴Centre of Excellence in Nutraceuticals, KSCSTE, Government of Kerala, Thiruvananthapuram 695317, Kerala, India

[†]These authors contributed equally to this work.

^{*}Correspondence: Ruby John Anto, Centre of Excellence in Nutraceuticals, KSCSTE, Government of Kerala, Thiruvananthapuram 695317, Kerala, India; Molecular Bioassay Laboratory, Institute of Advanced Virology, Bio-360 Life Science Park, Thiruvananthapuram 695317, Kerala, India; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, Kerala, India. cs.coen@kerala.gov.in; rjanto@iav.res.in



Graphical abstract. Classification of alkaloids with anti-inflammatory and anti-cancer properties

Keywords

Phytochemicals, cancer, inflammation, oncogenic pathways, chemoprevention

Introduction

Phytochemicals are bioactive compounds that are produced by plants as a means of protection from pathogens, such as bacteria, viruses, fungi, or parasites. They play an important role during stressful conditions and tend to accumulate in fruits and vegetables. During growth and development, plants produce numerous phytochemicals that help resist environmental stresses [1]. The richness of phytochemicals in plants has made them integral parts of traditional healing practices across diverse cultures for centuries. The earliest documented use of plant-based medicines can be traced back to ancient civilizations, including China (circa 5,000 BC), India (circa 2,000 BC), Mesopotamia (circa 2,600 BC), and Egypt (circa 1,550 BC). However, the dominance of synthetic medications surged in the initial decades of the twentieth century, due to their perceived efficacy and profitability [2].

Phytochemicals from a diverse array of plants have been found to confer various health benefits, exhibiting a spectrum of medicinal activities encompassing anti-inflammatory, antidiabetic, anti-aging, antibiotic, antiparasitic, antidepressant, anti-cancer, and antioxidant properties. Apart from these, they also contribute to combating wounds, cardiovascular abnormalities, Alzheimer's, Parkinson's, epilepsy, migraine, arthritis, schizophrenia, acne vulgaris, and various age-related diseases [3, 4]. Phytochemicals such as terpenes, carotenoids, monoterpenes (including perillyl alcohol and limonene), saponins, phenols (including polyphenols and flavonoids), organo-sulphur compounds (such as indoles, isothiocyanates, and thiosulfonates), organic acids, polysaccharides, and lipids (such as isoprenoids and omega-3/omega-6 fatty acids), sourced from fruits and vegetables, offer a diverse spectrum of health benefits [5].

Inflammation represents an evolutionary strategy in higher organisms, serving as a protective response against microbial infections and tissue injuries. This immune process is essential for eliminating harmful agents and facilitating tissue repair [6]. This key mechanism of post injury tissue repair has been linked to a broader spectrum of diseases beyond infection and injury [7]. Tumor-promoting inflammation emerges as a critical driver in cancer pathogenesis, affecting neoplastic transformation, tumor progression, metastasis, and recurrence. The induction of wound healing responses in tumor tissue stimulates cell survival, angiogenesis, and extravasation, with certain immune responses promoting tumor progression. Understanding the intricate interplay between inflammation and disease processes offers valuable insights into the development and progression of various pathological conditions, underscoring the importance of targeted therapeutic strategies aimed at modulating inflammatory responses [8].

Phytochemicals such as dihydrotanshinone, curcumin, and quercetin have demonstrated remarkable efficacy against inflammatory responses, in experimental models (in vitro) as well as living organisms (in vivo). This exceptional anti-inflammatory potential positions them as promising contenders for the development of safe anti-inflammatory medications [9]. The phytochemicals curcumin and resveratrol (RSV) have also been found to down-regulate major signaling pathways contributing to cancer and inflammation. Traditional remedies like *Saccharomyces cerevisiae* and plant-derived substances like colchicine, down-regulate inflammation by modulating cytokine production, showcasing their potential in

mitigating inflammation and pain associated with chronic ailments [10, 11]. Similarly, many flavonoids have been shown to impede tumor growth by intervening with inflammatory mechanisms, suggesting their potential applications in the prevention of diseases like breast and colorectal cancer (CRC), where chronic inflammation plays a significant role [11].

Cancer is a major global health issue, accounting for 10 million deaths in 2020. Common types of cancer include lung, breast, colon, prostate, and rectal cancers [12]. The GLOBOCAN database predicts over 35 million new cancer cases in 2050, a 77% increase from 20 million cases in 2022. Cancer is primarily caused by gene mutations, which change cell behavior and promote sustained cell proliferation [13]. Chemical compounds, smoke, viruses, bacteria, and radiation can contribute to carcinogenesis. Mutations in proto-oncogenes, which are responsible for cell division and growth, can convert them to oncogenes, which disrupt the normal cell division mechanism leading to cell transformation [14]. Mutations that inactivate tumor suppressor genes may also result in uncontrolled cell division and tumor formation. Furthermore, epigenetic modifications such as DNA methylation, histone modifications, and nucleosome position, which are also crucial for the proper regulation of cell growth and development, can also contribute to the neoplastic process [15].

A large variety of plant-derived chemicals have been found to possess properties that impede tumor invasion and metastasis by various mechanisms, such as disruption of signaling pathways that regulate epithelial-mesenchymal transition (EMT) processes or prevent migration and invasion of cancer cells [16]. Moreover, specific phytochemicals such as saponins, phenolic compounds, and terpenoids, including genistein and curcumin, can target molecular pathways regulating angiogenesis, thereby restricting nutrient and oxygen supply to tumors [17]. Additionally, alkaloids, terpenes, and polyphenols can inhibit cancer cell proliferation and growth, while many other plant extracts appear to modulate cell cycle and cell death regulating proteins such as BH3 interacting-domain death agonist (Bid), B-cell lymphoma 2 (Bcl-2)-associated protein x (BAX), and Bcl-2, inducing cancer cell death via apoptosis [18]. Figure 1 illustrates the major hallmarks of cancer and inflammation, targeted by phytochemicals. Many plant-derived compounds have been reported to hinder tumor progression by modulating biochemical pathways, such as glycolysis, the pentose phosphate pathway (PPP), the tricarboxylic acid (TCA) cycle, and serine metabolism [19]. Phytochemicals like shikonin and hypericin promote immune mediated cancer cell destruction [20]. In summary, the multifaceted anti-inflammatory actions of phytochemicals underscore their significance as both preventive and therapeutic agents in cancer and inflammation.

Classification

Generally, phytochemicals have been classified as primary or secondary metabolites based on their role in plant metabolism. Primary metabolites are directly involved in growth and metabolism and include common sugars, amino acids, proteins, nucleic acid purines and pyrimidines, and chlorophylls [21]. Secondary metabolites are products of the primary metabolism and are involved in a range of metabolic activities. They are grouped into different classes depending on their chemical structure, botanical origin, biosynthesis pathway, or biological properties [22]. Based on the chemical structure of the compounds, they are classified into polyphenols (flavonoids and non-flavonoids), alkaloids, terpenoids, and saponins [2, 5, 10, 23, 24]. Plant derived alkaloids, polyphenols, and terpenoids constitute the most significant group of pharmacologically active compounds [3]. The terpenoids can be subcategorized into carotenoids and non-carotenoid terpenoids. Other phytochemical groups, which share some properties with the abovementioned groups, have been classified into a miscellaneous category, which consists of organo-sulphur compounds and non-sulphur-containing indoles [25].

The major classes of phytochemicals are listed in Table 1, while the chemical structure of the major phytochemicals that are discussed in this review is presented in Figure 2.

Polyphenols

Natural biophenols, synthesized by plants as secondary metabolites, predominantly for defense against pathogens, exhibit diverse roles and contribute significantly to the flavor, color, and nutritional value of




Figure 1. Involvement of phytochemicals in modulation of cancer cell growth and inflammation-dependent diseases

plant-derived foods. These compounds are broadly categorized into two major groups: flavonoids and non-flavonoids. Research suggests that polyphenols, which are abundant antioxidants in the diet, may improve insulin resistance, reduce inflammation and oxidative stress, and slow aging process [25, 26]. They also show promise in addressing age-related symptoms such as oxidative stress, inflammation, proteostasis impairment, cellular senescence, thrombosis, and tumor development.

Flavonoids

Flavonoids are a large group of plant secondary metabolites, with a common phenyl benzopyrone structure. They are one of the largest groups of secondary metabolites, with over 2,000 naturally occurring compounds. They are classified into two main groups based on the saturation level of the central heterocyclic ring [27]. Unsaturated flavonoids include anthocyanidins, flavones, flavonois, and isoflavones, while saturated flavonoids include flavanones, dihydroflavonols, and flavan-3-ols [28]. Flavonoids are generally found to be conjugated with sugars as glycosides or in ester or polymer forms [29]. The antioxidant capacity of flavonoids is determined by the positioning of the catechol B-ring on the pyran C-ring, as well as the quantity and arrangement of hydroxy groups on the B-ring [30]. Flavonoids originate from two distinct biosynthetic pathways viz; the phenyl propanoid pathway, which is responsible for the phenyl propanoid skeleton, and the polyketide pathway, which generates polymeric building blocks [31]. These compounds offer various therapeutic benefits, such as antioxidant activity, cardiovascular protection, anti-inflammatory effects, neuroprotection, and anti-platelet aggregation [32]. Additionally, flavonoids play a crucial role in cancer prevention by influencing processes such as apoptosis, necrosis, cell cycle arrest, and autophagy [33]. Some selected compounds from this category are discussed below.

Table 1. List of major classes and subclasses of phytochemicals and other sources

Major class	Subclass	Compounds	Source
Polyphenols- flavonoids	Flavanols	Catechins, proanthocyanidins, epigallocatechin	Apricots, apples, peaches, green tea, and chocolate
	Flavonols	Kaempferol, quercitin	Broccoli, onions, radish, and blueberries
	Flavones	Luteolin, apigenin	Celery, lettuce, and capsicum peppers
	Isoflavones	Genistein, daidzein	Soya and its processed products
	Flavanones	Hesperetin, naringenin	Citrus fruits like oranges and grapefruits
	Anthocyanidin	Cyanidin, delphinidin	Red wine, berry fruits, and colored fruits
Polyphenols-non- flavonoids	Lignans	Pinoresinol	Flaxseeds and sesame seeds
	Stilbenes	Resveratrol	Grapes, pomegranate, berries
	Phenolic acids	Ferulic acid, caffeic acid, ellagic acid, vanillic acid	Coffee, berries, onions, cereals, and legumes
	Curcumins	Curcumin, demethoxycurcumin, cyclic curcumin	Rhizomes of turmeric
Saponins	Cycloartane saponins	Uttroside B, timosaponin A-III	Medicinal plants
	Dammarane saponins		
	Oleananes		
	Spirostanes		
	Furostanes		
Terpenes	Monoterpenoids	Thymoquinone	Nigella sativa
	Diterpenoids	Paclitaxel	Bark of the Pacific yew tree
	Triterpenoids	Ursolic acid	Marjoram leaves, oregano leaves, rosemary, and wax layer of edible fruits
		Cucurbitacin	Cucurbitaceae plants
Alkaloids		Tryptanthrin	Bacteria, fungi, and plants like Couroupita guianensis, Wrightia tinctoria
		Cepharanthine	Stephania tubers
		Oxysophocarpine	Robinia genus plants
Miscellaneous compounds	Organosulfur compounds	Sulforaphane, allicin, isothiocyanates	Garlic, onions, and cruciferous vegetables like broccoli, cauliflower, and cabbage
	Polysaccharides	Pectin	Citrus fruits and apples

Flavonoids are classified into seven subclasses, based on their structural differences. This includes flavanols, flavones, isoflavones, anthocyanidins, flavanones, flavonols, and chalcones [34, 35]. Flavones are characterized by a double bond between C2 and C3 and a ketone group at C4 position. They are commonly found in parsley and celery, with examples like apigenin and luteolin which are known for their anti-inflammatory and anticancer properties [36]. Flavanols have an additional hydroxyl group at C3 and are present in onions, kale, and berries, exhibiting strong antioxidant activities. Examples of this include quercetin and kaempferol [37]. Flavan-3-ols, like catechin and epicatechin, have a hydroxyl group at C3 and are found in green tea and cocoa, noted for their cardiovascular benefits [37]. Anthocyanidins are flavonoids without a ketone group at C4 position. They are responsible for red, blue, and purple pigmentation in plants such as berries and grapes, and include cyanidin and delphinidin, which are well-known for their antioxidant properties [38]. Isoflavanoids, with the B ring attached to C3, are found in soybeans and include genistein and daidzein, beneficial for menopausal symptoms and osteoporosis [39]. Chalcones, with an open-chain structure, are present in apples and strawberries, with examples like phloretin, and are known for their anti-inflammatory and antimicrobial activities [40].

Some selected compounds from this category are discussed below.

Kaempferide

Kaempferide, a compound with multifaceted therapeutic potential, exhibits a range of anti-inflammatory properties that make it a promising candidate for treating various inflammatory conditions [41].




Figure 2. Chemical structures of phytochemicals discussed in this review. EGCG: epigallocatechin 3-gallate. The Figure was generated using ChemDraw with images sourced from Pubchem [kaempferol (PubChem Identifier: CID 5280863); EGCG (PubChem Identifier: CID 65064); luteolin (PubChem Identifier: CID 5280445); anthocyanin A1 (PubChem Identifier: CID 154824275); p-coumaric acid (PubChem Identifier: CID 637542); p-salicylic acid (PubChem Identifier: CID 135); macelignan (PubChem Identifier: CID 10404245); resveratrol (PubChem Identifier: CID 445154); curcumin (PubChem Identifier: CID 969516); uttroside B (PubChem Identifier: CID 44566638); timosaponin A III (PubChem Identifier: CID 155887663); paclitaxel (PubChem Identifier: CID 36314); ursolic acid (PubChem Identifier: CID 64945); evodiamine (PubChem Identifier: CID 10281); cucurbitacin B (PubChem Identifier: CID 5281316); ginsenoside Rg3 (PubChem Identifier: CID 9918693); tryptanthrin (PubChem Identifier: CID 73549); berberine (PubChem Identifier: CID 2353); cepharanthine (PubChem Identifier: CID 10206); oxysophocarpine (PubChem Identifier: CID 161544)]

Specifically, it has been shown to suppress the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin 1 β (IL-1 β), and IL-6, which play crucial roles during the inflammatory response. By inhibiting the nuclear factor kappa B (NF- κ B) pathway, a central regulator of inflammation, kaempferide effectively reduces the production of inflammatory mediators, thereby

mitigating the inflammatory process [41]. Kaempferide also exhibits anti-obesity, hypoglycemic, and hypolipidemic effects, which are achieved through inhibition of the Toll-like receptor 4 (TLR4)/inhibitor of NF- κ B α (I κ B α)/NF- κ B pathways [42]. Kaempferide demonstrates potent anti-photoaging properties, exemplified by its ability to inhibit collagen degradation, inflammatory responses, subcutaneous fat, UVB-induced reactive oxygen species (ROS)-mediated signaling pathways, and inhibit signaling effector proteins such as mitogen-activated protein kinases (MAPKs) [extracellular signal regulated kinase (ERK), p38, and C-Jun N-terminal kinase (JNK)] and protein kinase B (AKT) [41]. The kaempferide anti-inflammatory effects also contribute to preserving cardiac steady-state function [43].

In addition to its myriad anti-inflammatory attributes, kaempferide is extensively investigated for its anti-cancer properties. To the best of our knowledge, our group was the first to report the anti-cancer potential of kaempferide against cervical cancer, wherein the compound isolated from *Chromolaena odorata* was found to inhibit the growth of HeLa cells in vitro [44]. It emerges as a potent against various types of cancer, including lung adenocarcinoma, hepatocellular carcinoma (HCC), and cervical cancer [45]. The mechanism of action of kaempferide involves the regulation of onco-proteins and tumor suppressor proteins, which results in the inhibition of cancer cell growth. Kaempferide acts as a promising alternative against HCC by down-regulating transforming growth factor- β 1 (TGF- β 1), a crucial marker of liver cancer metastasis [46]. It also exhibits remarkable efficacy in attenuating UVB-induced skin aging processes and in enhancing cancer cell sensitivity to doxorubicin [47]. A recent study from our lab has revealed that in cervical cancer cells, kaempferide suppresses the expression of the human papilloma virus (HPV) onco-proteins, E6 and E7, two proteins that are pivotal regulators of cervical tumorigenesis [48].

Epigallocatechin 3-gallate

Epigallocatechin 3-gallate (EGCG), a potent catechin and a major component of green tea, is derived from the formal condensation of gallic acid with (-)-epigallocatechin. It is naturally present in an array of plant sources, including *Limoniastrum guyonianum* and *Scurrula atropurpurea*. EGCG is a prominent polyphenol that has garnered significant attention due to its multifaceted attributes, including antioxidant, anti-inflammatory, anti-cancer, and anti-diabetic properties [49].

EGCG exhibits broad anti-inflammatory effects. It was found to ameliorate brain inflammation and demyelination damage in experimentally-induced autoimmune encephalomyelitis (EAE). Through a complex interplay of cellular mechanisms, EGCG not only displays neuroprotective benefits but also showcases remarkable efficacy against a spectrum of infections [50]. From battling viruses like human immunodeficiency virus (HIV), influenza, and hepatitis C to combating drug-resistant bacterial strains such as methicillin-resistant *Staphylococcus aureus* (MRSA) and even human-pathogenic yeasts like *Candida albicans*, EGCG emerges as a versatile health-promoting compound [51, 52]. Its anti-inflammatory prowess is evidenced by its ability to inhibit cyclooxygenase (COX) enzymes and reduce the expression of pro-inflammatory cytokines [53]. Moreover, by obstructing the activation of the epidermal growth factor receptor (EGFR) and its downstream signaling mechanisms, EGCG offers promising prospects for alleviating neuroinflammation in neurodegenerative diseases [53].

EGCG demonstrates potent cancer preventive and therapeutic potential by impacting on diverse signal transduction pathways. It modulates the ERK, inhibits PI3K-AKT, and sensitizes cells to TNF related apoptosis inducing ligand (TRAIL) thereby protecting cells from oxidative stress-induced apoptosis [50]. In breast cancer, EGCG exhibits multiple benefits by controlling cell proliferation, invasion, and apoptosis, and inhibiting inflammation and DNA demethylation. Its chemotherapeutic effects involve micro-RNA regulation, cellular communication network factor 5 (CCN5) activation, and inhibition of estrogen receptoralpha (ER- α). EGCG sensitizes triple negative breast cancer cells to estrogen by activating ER- α , resulting in decreased cell viability [54, 55]. In HCC, EGCG prevents and inhibits tumor development through mechanisms that include reduction of oxidative stress and modulation of cell proliferation, invasion, and apoptosis. It enhances the efficacy of chemotherapy, radiotherapy, and targeted therapy in HCC [56, 57]. It has been reported that EGCG decreases the expression of androgen receptor (AR) and prostate-specific

antigen (PSA) in the prostate cancer cell line, LNCaP. It inhibits vasculogenic mimicry by down-regulating the twist/VE-cadherin/AKT pathway in human prostate cancer cell line, PC-3 [58, 59]. In CRC, EGCG was found to induce ubiquitination and subsequent degradation of the large tumor suppressor kinase 1 (LATS1)/LATS2 kinase via the E3 ligase, carboxyl terminus of Hsp70 interacting protein (CHIP), resulting in the activation and nuclear translocation of Yes-associated protein (YAP), which is implicated in CRC progression and chemotherapy resistance [60].

Luteolin

Luteolin, primarily derived from *Salvia tomentosa*, occurs in both aglycone and glycoside forms and exhibits a diverse repertoire of physiological benefits [57, 61]. Recognized for its tetrahydroxyflavone structure, luteolin embodies a multifunctional role and functions as an antioxidant and anti-inflammatory agent, as well as a modulator of the immune system and an inhibition of cancer progression [62]. It scavenges free radicals, shields against damage induced by ROS, and impedes tumor progression and metastasis by orchestrating cell cycle arrest and apoptosis [63].

The anti-inflammatory role of luteolin has garnered significant attention in scientific research. Luteolin has been shown to inhibit the release of lipopolysaccharide (LPS)-induced TNF- α through the inactivation of ERK and p38 MAPK signaling pathways and block NF- κ B transcriptional activation [64]. Through its inhibitory effects on NF- κ B and AP-1 signaling pathways, luteolin down-regulates the expression of TLR3 and impedes NF- κ B p65 translocation, thus exerting a comprehensive regulatory influence on inflammatory cascades [65]. Furthermore, luteolin has been shown to mitigate the expression of inflammatory cytokines and attenuate NF- κ B p65 activity within the hypothalamus, attesting to its potential effects in neuroinflammatory conditions [66]. Additionally, in conjunction with other phytochemicals, luteolin has been found to be effective in mitigating inflammatory markers such as TNF- α and COX-2 in rodent models of cadmiuminduced toxicity [67]. These findings underscore the potential of luteolin as a multifaceted anti-inflammatory remedy for diverse inflammatory conditions.

Luteolin emerges as a formidable contender in the fight against cancer, targeting multiple pathways involved in oncogenesis [68]. It was shown to regulate the expression of pivotal proteins such as AKT, Pololike kinase 1 (PLK-1), and cyclins, associated with cancer progression, while enhancing the activity of apoptotic regulators, such as BAX and caspase-3, thus tipping the balance in favor of cell death [69]. Moreover, inhibition of signal transducer and activator of transcription 3 (STAT3) signaling by luteolin renders cancer cells more susceptible to conventional radiotherapy and chemotherapy, amplifying their efficacy [68]. Similarly, in prostate cancer, luteolin hinders tumor development, reduces cell growth, and suppresses cancer stemness via the inhibition of enhancer of zeste homolog 2 (EZH2) [70]. Additionally, luteolin demonstrates notable anti-tumor activity in HCC, disrupting cell survival, angiogenesis, and cellular recycling mechanisms [71-73]. In cervical cancer, luteolin emerges as a promising candidate for therapeutic intervention by inhibiting cell invasiveness, suppressing hypoxia inducible factor 1 subunit alpha (HIF-1α) signaling, and targeting key oncogenes, including the ubiquitin conjugating enzymes E2S (UBE2S). The ability of luteolin to inhibit HPV E6 and E7 oncogene expression further underlines its potential as a vital component in the treatment arsenal against cervical cancer [74, 75]. In essence, the multifaceted actions of luteolin against various types of cancer underscore its promise as a therapeutic agent with far-reaching implications in oncology.

Fisetin

Fisetin (FST), is a natural flavonoid compound, isolated from Venetian sumac. It is found in various plants, including their green parts, fruits, bark, and hardwood. FST is present in various fruits and vegetables, such as strawberries, apples, persimmons, grapes, onions, and cucumbers. FST possesses various health benefits such as anti-oxidant, anti-inflammatory, anti-microbial, neuroprotective, hepatoprotective, anti-obesity, anti-depressant, and anti-cancer effects [76]. Studies have revealed that FST exerts anti-cancer activity via inhibiting the cell signaling pathways, including those involved in inflammation, apoptosis, angiogenesis, growth factor regulation, and transcription factors [77].

FST reduces inflammation, a critical factor in cancer development. It inhibits pro-inflammatory mediators and improves inflammatory injury and oxidative stress caused by LPS. Clinical trials with CRC patients showed significant decreases in inflammatory markers C-reactive protein (CRP) and IL-8 with FST supplementation [78]. FST down-regulates the NF- κ B pathway, which is involved in cell survival and proliferation. It increases I κ B α expression, reduces NF- κ B nuclear translocation, and suppresses NF- κ B target genes, leading to decreased cell proliferation and enhanced apoptosis in bladder and melanoma cancer cells [79].

FST activates apoptotic markers including poly(ADP-ribose) polymerase (PARP) and caspase 3, suppresses the anti-apoptotic proteins, and enhances pro-apoptotic ones to make cancer cells more sensitive for programmed cell death in head and neck, uveal melanoma, or renal carcinoma. FST also triggers autophagy in pancreatic and oral squamous cell carcinoma cells, marked by the up-regulation of autophagy-related proteins like microtubule-associated proteins 1A/1B-light chain 3B (LC3B) and Beclin-1. This process helps in eliminating cancer cells by promoting cellular stress responses that lead to cell death. FST causes cell cycle arrest at the GO/G1 phase, preventing the proliferation of cancer cells. It increases the expression of cell cycle inhibitors like p21 and p53 while down-regulating cyclins and cyclin-dependent kinases (CDKs) that drive cell cycle progression, effectively halting tumor growth. It down-regulates vascular endothelial growth factor receptor (VEGFR) expression and reduces VEGF levels, impairing the vascular network that supplies nutrients to tumors, thereby stunting angiogenesis. FST also inhibits pathways such as PI3K/AKT/mTOR, STAT3, and wingless-related integration site (Wnt)/ β -catenin, which are essential for cell growth, cell proliferation, differentiation, metastasis, and survival [80].

Non-flavonoid

Non-flavonoid molecules represent a diverse group of phytochemicals that include phenolic acids, lignans, tannins, and stilbenes, each with unique structural and functional properties. Among these, phenolic acids stand out as the most prevalent category of phytochemicals, characterized by aromatic rings linked to organic acids such as cinnamic and benzoic compounds [81].

Phenolic acid

Phenolic acids are aromatic compounds characterized by their organic carboxylic acid and phenolic ring functionalities, which play a pivotal role in plant defense mechanisms against various environmental stresses, including UV radiation, pathogens, and chemical insults [82]. This diverse group of secondary metabolites is broadly categorized into two main classes, namely benzoic acid derivatives and cinnamic acid derivatives, distinguished by the position of the carboxylic acid group relative to the phenol ring [83, 84].

The abundance of hydroxybenzoic acids in fruits such as strawberries and raspberries and hydroxycinnamic acids in cereals, legumes, vegetables, and beverages underlines their importance in human nutrition. These compounds exhibit a wide range of properties, including antioxidant, antibacterial, anti-cancer, cardioprotective, immunomodulatory, anti-inflammatory, and skin-protective effects [84, 85].

Research over the years has demonstrated the potential of phenolic acids in combating oxidative stress-related diseases, especially coronary heart disease, stroke, and certain cancers, owing to their potent antioxidant activities [86]. Moreover, their anti-inflammatory effects extend to diverse tissues like the placenta and adipose tissue, suggesting their broader therapeutic applications [86]. Notably, *Moringa oleifera* leaves have emerged as a promising natural source of phenolics with neuroprotective and metabolic benefits. Studies have reported their ability to reduce DNA damage, modulate the activity of enzymes like acetylcholinesterase (AchE) and caspase-3, and improve the management of diabetes through the enhancement of insulin sensitivity and lipid metabolism [87]. Furthermore, phenolic-rich extracts from common beans, quince fruit, and pomegranate peel have been found to reduce inflammatory processes [88–90].

Phenolic bioactive compounds demonstrate anti-invasion and anti-metastasis properties by modulating the activities of critical proteins like protein kinase C (PKC), focal adhesion kinase (FAK), and cell division control protein 42 (Cdc42), while orchestrating the intricate phosphorylation of signaling molecules including Ras, Ras related C3 botulinum toxin substrate 1 (Rac1), ERK, JNK, p38, PI3K, p70S6K, p21 activated kinase 1 (PAK1), AKT, Ras homolog family member A (RhoA), and RhoB [91]. Consequently, this molecular ballet leads to the suppression of key transcription factors such as AP-1, NF-κB, and STAT3 [92], thus preventing the progression of cancer cells.

Lignans

Lignans represent a distinctive class of secondary plant metabolites arising from the oxidative dimerization of two phenylpropanoid units (C6-C3) via the shikimic acid and phenylpropanoid pathway [93]. These compounds, composed of two phenylpropane units, are predominantly sourced from linseed, cereals, grains, fruits, and select vegetables [94]. Plant lignans and their metabolites are recognized for their remarkable properties, which include antioxidant, anti-inflammatory, anti-cancer, neuroprotective, cardioprotective, and chemopreventive.

Novel lignan compounds, such as ecdysanols A-F, dibenzocyclooctadiene, and aryl naphthalene lignans from *Kadsura coccinea* roots exhibits significant anti-inflammatory effects, suggesting their potential usage in conditions such as rheumatoid arthritis [95]. Similarly, lignans extracted from *Ferula sinkiangensis* resin, schisandrin A from *Schisandra chinensis*, and aryl naphthalide lignans from *Schisandra medusa* exhibit antioxidative and anti-inflammatory effects, making them promising drug candidates for diabetes and for neuroprotection [93]. Extracts from the roots of *Krameria lappacea*, traditionally used for oropharyngeal inflammation, contain lignan derivatives that possess anti-inflammatory, anti-edematous, and antioxidant properties [96]. Lignan-enriched extracts from *S. chinensis* and *Schisandra rubriflora* show enhanced anti-inflammatory activity, with individual lignans exhibiting inhibitory effects against enzymes such as 15-lipoxygenase (15-LOX), COX-1, and COX-2 [97]. Additionally, the lignans, 7-hydroxymatairesinol and 7-hydroxymatairesinol 2, found in cereals, exhibit potent anti-inflammatory effects in endothelial cells, in which they down-regulate NF-κB and ERK [97].

Several investigations have revealed that lignans are likely to function as candidates for chemotherapeutic and chemopreventive applications. Their anti-cancer efficacy is attributed to their capacity to induce apoptosis, impede cell proliferation, and suppress metastasis and angiogenesis [98]. Western European diets rich in flavonols and lignans are associated with a 25% lower risk of bladder cancer, particularly urothelial cell carcinomas [99]. Lignan intake from sources like sunflower seeds and soybeans is linked to a reduced risk of breast cancer [100]. However, it's crucial to note that the stability of sesame oil relies on lignans and unsaturated fatty acids, necessitating careful processing to preserve its nutritional integrity [101]. Macelignan, derived from nutmeg, has been reported to inhibit M2 macrophage polarization and suppress cancer cell metastasis [102]. Lignans abundant in flaxseed, such as secoisolariciresinol diglucoside and honokiol, exhibit anti-cancer effects against breast cancer by enhancing cytotoxicity in vitro and by promoting apoptosis in resistant tumors [103]. Furthermore, olive oil-derived compounds particularly (+)-1-acetoxypinoresinol and (+)-pinoresinol, have been reported to function as significant modulators of cancer chemopreventive activity, especially in breast, colon, and prostate cancers [104].

Stilbenes

Stilbenes (or stilbenoids) are widely distributed in food (grapes, peanuts, and other foods) and medicinal plants [105]. Stilbenes contain a carbon backbone of C6-C2-C6 and two benzene rings joined by a molecule of ethanol or ethylene. They exist in the trans-((E)-stilbenes) and cis-((Z)-stilbenes) 1,2-diphenylethylene structures. Among them, RSV, which is abundant in grapes, exhibits remarkable health benefits and is under extensive investigation [106].

Resveratrol

RSV (3,4',5-trans-trihydroxystilbene) is a phenolic stilbene that is abundant in grapes as well as in blueberries, raspberries, peanuts, and red wine [107]. It is a phytoalexin and is synthesized by plants in response to stress, injury, and ultraviolet irradiation [108]. RSV possesses a unique chemical structure consisting of two phenol rings linked by a double styrene bond and consists of both *cis* and *trans* structures [109].

The versatile properties of RSV make it an intriguing candidate for the prevention and therapy of multiple human diseases. Studies have shown that RSV exhibits a broad spectrum of health benefits, encompassing cardio-protection, anti-inflammatory, antioxidant, anti-diabetic, anti-aging, skin depigmentation, cancer prevention, antimicrobial, and neuroprotective properties [110–112].

RSV exhibits beneficial health related effects in a range of neurological diseases and inflammatory conditions, including depression, Alzheimer's disease, and inflammatory bowel disease [113].

Its mechanism of action involves the down-regulation of pro-inflammatory cytokines through modulation of the NF- κ B pathway, along with a brain-specific reduction in phosphorylation levels and activity of cAMP response element binding (CREB) protein and brain derived neurotrophic factor (BDNF) [114]. Preliminary studies have demonstrated that RSV is effective in treating depression, Alzheimer's disease, and inflammatory bowel diseases. RSV-maltol hybrids have metal chelating properties and antioxidant effects, potentially addressing Alzheimer's disease by inhibiting aggregation of A β 1-42 [115]. Orally administered RSV, curcumin, or simvastatin can alleviate small intestinal inflammation, prevent bacterial translocation, and maintain gut barrier functions [116]. RSV was also found to exhibit protective effects against cartilage destruction and synovial inflammation [117].

RSV has been shown to possess a wide range of anti-cancer effects, exhibiting diverse mechanisms of action against distinct types of cancer. It reduces paclitaxel-induced cell death in MDA-MB-435s, MDA-MB-231, and SKBR-3 cell lines, apparently by the inhibition of G2/M cell cycle arrest and suppression of ROS production. As a result, RSV inactivates the anti-apoptotic Bcl-2 family proteins, suggesting potential damage following the RSV co-administration with paclitaxel in selected human cancers [118]. RSV was found to modulate the LPS-induced EMT in PC-3 and LNCaP prostate cancer cells, by effectively inhibiting the expression of EMT markers and by reducing cell motility via inhibition of the hedgehog signaling pathway [119]. RSV also inhibits cell proliferation and regulates the apoptosis-related genes *Bcl-2* and *BAX* in non-small cell lung cancer (NSCLC) cell lines, as well as in a mouse model of implanted primary gastric cancer cells, resulting in which a dose-dependent inhibition of carcinoma growth was observed [120, 121]. A study from our lab has established that RSV enhances the efficacy of docetaxel chemotherapy in breast cancer cells over-expressing HER2, through the HER-2-AKT signaling axis [122]. Moreover, it cooperatively suppresses cancer cell viability and invasion with cisplatin, via selected signaling pathways [123].

3,5-Dihydroxy-4-ethyl-*trans*-stilbene

3,5-Dihydroxy-4-ethyl-*trans*-stilbene (DETS), which is structurally similar to RSV, was studied in our lab and was found to down-regulate key molecules involved in melanoma progression, leading to cell cycle arrest at the S-G2 transition phase. To the best of our knowledge, this marks the first report on DETS's antioxidant and anti-cancer properties, akin to RSV, from our lab [124]. DETS exhibits anti-proliferative and pro-autophagy effects on breast cancer stem cells (CSCs) which suppresses the Wnt/ β -catenin pathways [125]. In ovarian cancer, DETS has been shown to exhibit more potent anti-proliferative effects compared to RSV. Both compounds were found to impede the AKT and MAPK signaling pathways, inhibit IL-6 and EGF-dependent cell migration, and downregulate the expression of EMT markers in ascites-derived cancer cells [126].

Curcumin

Curcumin, also known as diferuloyl methane [1,7-bis(4-hydroxy-3-methoxy phenyl)-1,6-heptadiene-3,5-dione; $C_{21}H_{20}O_6$], is a lipophilic polyphenol extracted from the rhizomes of turmeric (*Curcuma longa*), a member of the ginger family, which is native to Asia, particularly India [127]. The term "curcuminoid"

refers to a set of compounds that resemble curcumin, such as demethoxycurcumin and cyclic curcumin [128]. Curcumin is an orange-yellow crystalline powder that turns brownish-red under alkaline conditions and light-yellow under acidic conditions [129]. Though soluble in alcohol and glacial acetic acid, its limited water solubility hinders absorption and leads to low bioavailability [130]. Despite this limitation, its safety profile has led to Food and Drug Administration (FDA) approval for high doses, and it is recognized for its multifaceted health benefits, such as blood-purifying, hepatoprotective, anti-inflammatory, antioxidant, anti-atherosclerotic, antidiabetic, and anti-cancer properties [131].

Being a lab focusing on various therapeutic aspects of natural products, we have evaluated curcumin as a chemotherapeutic, chemopreventive, and chemosensitizer and have validated its efficacy using various tumor models [132-135].

Moreover, studies have explored curcumin's impact on conditions such as osteoporosis and osteoarthritis, where it promotes bone health and suppresses inflammatory responses. It appears to alleviate the above symptoms by reducing the production of ROS [136]. Furthermore, curcumin effectively down-regulates inflammation by modulating cellular responses through the up-regulation of MAPK phosphatase 5 (MKP5) mRNA and inhibition of p38 phosphorylation [137].

Curcuminoids have gained significant attention in cancer research. It has been reported that curcumin exerts anti-carcinogenic effects by promoting apoptosis, arresting the cell cycle, and suppressing the expression of growth factor receptors [138]. Ours is one of the pioneer studies, which has evaluated the anticancer potential of curcuminoids using in vitro and in vivo models [139]. We have also evaluated many natural and synthetic curcuminoids for their antimutagenic and anticarcinogenic potential, using murine models [140]. Curcumin niosomes (curcusomes) characterized by their small size and enhanced antioxidant potential, hold promise for treating ovarian cancer [141]. Studies of the anti-cancer effects of curcuminoids also emphasize the potential synergy with conventional anti-cancer agents, such as piperine, which significantly increases the drug's bioavailability [142, 143]. Combination therapies involving curcumin with chemotherapeutic agents have demonstrated safety in murine models, with molecular docking analyses revealing curcumin's targeted therapeutic approach [144]. An innovative strategy involving the synthesis of curcumin-RSV hybrid compounds has been proven to improve pharmacodynamic and pharmacokinetic properties while reducing the toxicities associated with the parent drug. Beyond oncology, research has unveiled curcumin's potential across a range of metabolic and musculoskeletal conditions such as polycystic ovary syndrome, metabolic syndrome, cardiovascular diseases, and Achilles tendinopathy [131, 145].

Saponins

Saponins are glycosidic compounds found in various plants and offer diverse applications in the food, agriculture, and pharmaceutical industries [146]. These compounds hold therapeutic promise with hypolipidemic, hypoglycemic, antioxidant, and antimicrobial activities, though they also present adverse effects such as cytotoxicity to normal cells [147]. The composition and bioavailability of saponins in food are significantly influenced by processing technologies, given their complex structure and low bioavailability [148]. Moreover, saponins interact with the gastrointestinal and gut environments, altering gut microbiota composition and its own biotransformation into sapogenins [149]. Saponins extracted from green tea exhibit therapeutic potential in mammalian cells by targeting cytotoxicity, angiogenesis, inflammation, and antioxidant activity. They exhibit cytotoxic effects on cancer cells, hinder HUVEC proliferation, scavenge free radicals, and suppress pro-inflammatory cytokines [150]. Even though saponins are traditionally considered anti-nutritional factors, recent studies highlight the pharmacological potential of saponins, emphasizing the importance of understanding their structural composition, which is categorized into triterpenoid and steroidal classes based on the carbon skeletons that dictate their biological activities [151].

Major saponins with anti-cancer potential include cycloartane saponins, dammarane saponins, oleananes, spirostanes, and furostanes. Cycloartane saponins display anti-cancer effects, along with

antioxidant, neuroprotective, hepatoprotective, and antiviral properties [152]. Dammarane saponins, found in medicinal plants, exhibit anti-inflammatory properties, cytotoxicity against tumor cell lines, selectively targeting malignant cells, and inducing apoptosis via calcium-dependent pathways [153]. Oleananes show diverse antitumor effects through various signal transduction pathways [154]. Spirostanes like polyphyllin D and dioscin display robust anti-cancer and immunostimulating activity, inducing apoptosis through mitochondrial dysfunction and ER stress [144]. Furostanes, a type of steroidal saponin, show limited but significant anti-cancer activity, acting as potential antineoplastic agents [155].

Uttroside B

Uttroside B (Utt-B), a saponin abundantly found in the roots, stem, and leaves of *Solanum nigrum*, has captured attention due to its potent cytotoxic properties against liver cancer cells. In vitro and in vivo studies from our laboratory have demonstrated the anti-HCC potential and pharmacological safety of Utt-B [156]. In a comparative analysis assessing the therapeutic efficacy of Utt-B against sorafenib, an established FDA-approved drug for HCC, Utt-B emerged as a superior anti-cancer agent in in vitro and in vivo experimental settings. Utt-B induced better cleavage of caspase-7 and down-regulation of the cell proliferation markers PCNA and Ki67, compared to sorafenib, resulting in a remarkable reduction in tumor size in mice harboring human HCC [157].

Furthermore, our investigations have revealed that Utt-B possesses the ability to induce pro-survival autophagy in liver cancer cells. This effect is mediated through the inhibition of mTOR signaling and activation of AMPK signaling, both pivotal in regulating autophagy in cancer cells. Interestingly, the inhibition of autophagy by chloroquine, a renowned anti-malarial drug and autophagy inhibitor, not only enhanced the anti-tumor efficacy of Utt-B but also improved the pharmacological safety, in vivo [158]. These findings strongly suggest the potential benefits of repurposing chloroquine in combination with Utt-B for the treatment of HCC, opening a promising avenue for future therapeutic interventions.

Timosaponin A-III

Timosaponin A-III (TSAIII) is a bioactive compound derived from the medicinal plant, *Anemarrhena* asphodeloides Bunge [159]. TSAIII is a white to off-white solid, soluble in methanol, butanol, 80% ethanol, and aqueous pentanol, but insoluble in water. The pharmacological effects of TSAIII are notably influenced by the sugar chain at the C-3 position. Specifically, the disaccharide form of TSAIII demonstrates greater activity compared to the monosaccharide TSAI, while the trisaccharide TSAV exhibits lower activity [160]. TSAIII exhibits efficacy against cancer development through various modes such as anti-inflammatory and antioxidant effects and inhibition of cell proliferation, induction of cell cycle arrest and apoptosis, initiation of autophagy, suppression of tumor cell migration, invasion, and angiogenesis [159].

TSAIII has been shown to inhibit the expression of various inflammatory mediators, including COX-2 and matrix metalloproteinase-9 (MMP-9) [144], and exert anti-inflammatory effects by inhibiting NF- κ B, a key player in the inflammatory response [161]. The compound exhibits remarkable efficacy across various cancer types through the intricate modulation of specific signaling pathways. In pancreatic cancer cells, TSAIII inhibits the PI3K/AKT pathway, leading to G1 phase arrest and apoptosis [162]. TSAIII activates ATM/Chk2- and p38 MAPK-regulated pathways to induce apoptosis in breast cancer cells and triggers mitochondria-mediated apoptosis in HepG2 cells [163]. In glioblastoma multiforme, TSAIII inhibits cell growth by down-regulating the Wnt/ β -catenin pathways [164]. Moreover, TSAIII has been reported to modulate autophagy by inhibiting the mTOR/Unc-51-like kinase 1 (ULK1) pathway, promoting autophagosome formation, and compromising tumor cell growth [165]. Furthermore, in NSCLC A549 cells, TSAIII inhibits the ERK1/2, proto oncogene tyrosine protein kinase (Src)/FAK, and β -catenin signaling pathways [166]. These findings underscore the diverse and promising therapeutic potential of TSAIII in targeting specific pathways critical for cancer progression and metastasis [167].

Ginsenoside Rg3

Ginsenoside Rg3, a dammarane-type ginsenoside, abundant in *Panax ginseng* and *Panax japonicus*, possesses hydroxy substitutions at the 3β, 12β, and 20 pro-S positions. This compound undergoes

transformations, such as the conversion of the 3-position hydroxy group into β -D-glucopyranosyl- β -D-glucopyranoside and the introduction of a double bond at the 24-25 position. It represents one among the more than 100 ginsenosides derived from *Panax ginseng*, historically revered in East Asia for its natural tonic properties [168]. These ginsenosides, including Rg3, manifest diverse pharmacological activities encompassing hepatoprotection, neuroprotection, cardiovascular protection, immune system enhancement, anti-fatigue properties, and antioxidant properties [169].

By inhibiting nucleotide-binding domain, leucine-rich-domain containing family, pyrin domain containing-3 (NLRP3) inflammasome activation and modulating gut microbiota homeostasis, Rg3 demonstrates efficacy in alleviating ulcerative colitis [170]. Moreover, Rg3 exhibits robust antioxidant and anti-inflammatory activities, validated in inflammation and oxidative stress models [171]. Rg3 extends its protective effects to diverse organs and systems. Rg3 has been reported to attenuate lung inflammation, prevent liver and kidney function damage, mitigate neuroinflammation, and offer protection against cerebral and myocardial ischemia/reperfusion (I/R) injury. Additionally, Rg3 shows promise in improving symptoms associated with hypertension and diabetes [171]. Studies also show that Rg3 directly inhibits LPS-mediated inflammation by targeting TLR4 signaling in macrophages [172]. These collective findings underscore ginsenoside Rg3 as a promising candidate for treating conditions characterized by inflammatory and oxidative stress.

Ginsenoside Rg3 showcases potent anti-cancer effects by targeting multiple signaling pathways across various types of cancer. In nasopharyngeal carcinoma (NPC), Rg3 has been found to sensitize cells to radiation therapy, curb radiation-induced EMT, and promote apoptosis [173]. In lung cancer, Rg3 impedes cell migration, invasion, and angiogenesis by suppressing the expression of COX-2 and VEGF [174]. Similarly, in renal cell carcinoma (RCC), Rg3 restricts cell migration, invasion, colony formation, and tube formation while enhancing apoptosis. These effects are achieved by promoting the demethylation of key genes such as p53, p21, and p16, along with histone acetylation [175]. Similarly, in prostate carcinoma, Rg3 was found to inhibit cell growth via modulation of the MAPK pathway [176].

Terpenoid

Terpenoids, also known as isoprenoids, encompass a wide range of natural compounds originating from the synthesis of isoprene and terpenes, which are polymers of isoprene. They are categorized based on the carbon arrangement formed by isoprene units, adhering to the isoprene rule [177]. The key building block of terpenoids is 2-methylbuta-1,3-diene (C_5H_8). Terpenoids are synthesized via the mevalonate (MVA) pathway or the 2-C-methyl-D-erythriol 4-phosphate (MEP) pathway, yielding hemi-, mono-, di-, and triterpenoids [178].

These compounds are further classified into subclasses such as monoterpenoids, sesquiterpenoids, diterpenoids, triterpenoids, and tetraterpenoids based on their structural characteristics [179]. Terpenoids are found abundantly in various plants, including *Commelina benghalensis* Linn., *Azadirachta indica* A. Juss., *Hypoestes* sp., *Carapa guianensis, Erica maesta*, and *Hohenbergia antillana*, Malagasy species like *Cussonia vantsilana*, *Helichrysum gymnocephalum*, *Phyllarthron madagascariense*, and *Gomphocarpus fructicosus* [93, 180–182]. Terpenoids have emerged as promising candidates for developing anti-inflammatory compounds, effectively addressing chronic joint inflammation, and impacting inflammatory mechanisms [183]. These compounds exhibit anti-inflammatory properties by inhibiting NF-κB activation, a key pathway in inflammation [184]. Specific terpenoids, such as carnosol and carnosic acid, have demonstrated significant inflammatory molecules like nitric oxide (NO), prostaglandin E2 (PGE2), and TNF, while also impeding the nuclear translocation of the NF-κB complex [186].

Terpenoids exert anticancer effects by inducing apoptosis, inhibiting cell proliferation, and suppressing angiogenesis [187]. They have also shown anti-cancer activities when used in combination with paclitaxel and vinblastine, which are already established effective chemotherapeutic agents [188]. These activities are attributed to their interaction with diverse molecular targets involved in cancer progression, including cell cycle regulators, signaling pathways, and DNA repair mechanisms [189].

Paclitaxel

Paclitaxel, a tetracyclic diterpenoid originally derived from the bark of the Pacific yew tree, *Taxus brevifolia*, emerged as a potent anti-cancer agent following a screening program by the National Cancer Institute in 1960 [190]. This compound, often obtained in needle form using aqueous methanol extraction or as a fine white powder, acts as a mitotic inhibitor in chemotherapy, specifically classified as a microtubule-stabilizing agent, a metabolite, a human metabolite, and an antineoplastic agent [191]. Originally known by the generic name "Taxol", its usage is now restricted due to its registration as a trademark. Isolated in 1971, it was discovered that endophytic fungi within *Taxus* species were responsible for its synthesis [192]. Administered intravenously for cancer treatment, paclitaxel is available in various formulations, such as abraxane, which features albumin-bound paclitaxel [193]. With a melting point in the range of 415°F to 421°F, paclitaxel gained approval by the US FDA 21 years after its discovery, initially for ovarian cancer and subsequently for breast cancer, solidifying its status as a highly effective anti-cancer agent [194].

Paclitaxel is renowned for its anti-inflammatory properties. In vitro studies reveal its ability to inhibit the activities of key enzymes involved in inflammation, namely COX-1, COX-2, and 5-LOX [195]. Paclitaxel has been reported to suppress the production of pro-inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 and promote the synthesis of anti-inflammatory cytokines like IL-10 [196]. In vivo studies show that paclitaxel treatment reduces the levels of inflammatory mediators such as inducible NO synthase (iNOS) and COX-2 [197]. These findings suggest that paclitaxel has the potential to suppress inflammation and may be beneficial in the treatment of inflammatory conditions.

Paclitaxel exerts significant anti-cancer effects through multiple mechanisms, including the induction of apoptosis, inhibition of cell proliferation, and suppression of angiogenesis. This compound interacts with diverse molecular targets implicated in cancer progression, encompassing regulators of the cell cycle, signaling pathways, and DNA repair mechanisms [198].

Studies conducted by our group have revealed interesting findings regarding the enhancement of the therapeutic efficacy of paclitaxel when combined with curcumin [135]. Pre-treatment with curcumin synergistically decreased tumor incidence and tumor volume in animals, exceeding the effects observed with either paclitaxel or curcumin alone. Interestingly, curcumin alone did not exhibit significant effects at the same concentration [135]. Another study from our lab reported that AKT functions upstream of NF- κ B in the signaling cascade triggered by paclitaxel and that complete inhibition of NF- κ B abolishes the synergistic effect between paclitaxel and curcumin [199].

Paclitaxel modulates critical pathways involved in breast cancer, including PI3K/AKT signaling, the Hippo pathway, microtubule stabilization, and DNA methylation, thereby influencing cell proliferation, apoptosis, and drug resistance. Paclitaxel has been reported to inhibit the PI3K/AKT/mTOR pathway in liver cancer, leading to reduced cell proliferation and migration alongside enhanced apoptosis [200]. Similar studies in colon cancer cells revealed that paclitaxel induces apoptosis by suppressing signaling pathways such as Janus kinases (JAKs)/STAT3 and PI3K/AKT/mTOR [201].

Ursolic acid

Ursolic acid (UA), a pentacyclic triterpenoid derived from various medicinal plants, exhibits notable pharmacological properties encompassing anti-inflammatory, antioxidant, antiapoptotic, and anticarcinogenic effects [202]. This compound is widely distributed across a range of botanical sources, including orchard apple, pomegranate, marjoram leaves, oregano leaves, rosemary, sage, thyme, lavender, eucalyptus leaves, black elder, hawthorn, coffee leaves, and the wax layer of various edible fruits [203].

UA has been shown to exhibit promising anti-inflammatory properties, particularly in treating skin conditions like eczema, psoriasis, and dermatitis [204]. Studies indicate that UA and its derivatives possess robust anti-inflammatory effects, capable of suppressing the production of inflammatory mediators [205]. Moreover, UA interferes with multiple inflammation-related signaling pathways, positioning it as a potential therapeutic option for inflammatory diseases [206].

Furthermore, UA has been reported to inhibit NF- κ B-mediated inflammatory pathways and enhance ROS-scavenging, elucidating the key mechanisms underlying its anti-inflammatory effects [207]. These findings highlight UA as a promising candidate for combating inflammation and suggest its potential in therapeutic interventions targeting inflammatory disorders.

UA has garnered considerable attention in research owing to its capacity to suppress the production of proinflammatory cytokines and its remarkable efficacy in combating various types of cancer. Studies show that UA not only inhibits cell viability and migration but also influences autophagy, apoptosis, and cell cycle progression. It is able to induce apoptotic effects, premature senescence, and even reverse paclitaxel resistance [208].

UA has been found to initiate pro-apoptotic signaling and disrupt mitochondrial function, leading to the activation of caspases 3, 8, and 9 in liver and gastric cancer. Moreover, in gastric cancer, UA targets the Hippo pathway, exhibiting inhibitory effects on tumor growth and promoting apoptosis [209]. In CRC, UA was found to inhibit cellular proliferation and induce apoptosis through modulation of signaling pathways crucial for cell cycle regulation and apoptosis [210]. UA also exhibits apoptotic activity against NSCLC by down-regulating the JAK2/STAT3 pathway and suppressing the expression of VEGF and PD-L1, thereby inhibiting tumor angiogenesis, migration, invasion, and metastasis [57]. Similarly, studies in skin cancer indicate that UA activates peroxisome proliferator-activated receptor α (PPAR α) and AMPK and induces apoptosis in mouse squamous cell carcinoma and skin papilloma [211].

Cucurbitacin B

Cucurbitacin B (CuB) is a tetracyclic triterpenoid commonly found in glycosidic forms [212]. It possesses a distinctive structural framework identified as 19- $(10\rightarrow9\beta)$ -abeo- 10α -lanost-5-ene, characterized by high unsaturation and multiple ketone groups [213]. The cytotoxicity of CuB is believed to be linked to the presence of a 25-acetoxy group, although studies indicate that saturating the conjugated 23(24) double bond may mitigate this effect [214]. Cus B, I, and E, among others, demonstrate promise in inhibiting selected types of cancer including breast, hepatocellular, laryngeal, lung, melanoma, pancreatic, and prostate cancers [215].

Remarkable anti-inflammatory properties of CuB are reflected in its ability to modulate various pivotal regulators of signaling pathways, including JAK/STAT3, Nrf2/antioxidant response element (ARE), NF-κB, AMPK, MAPK, PI3K/AKT, cancerous inhibitor of protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A), Wnt, FAK, Notch, and Hippo-YAP [216]. Additionally, CuB holds promise for attenuating cerebral I/R injury by inhibiting inflammation mediated by the NLRP3 inflammasome and reducing oxidative stress [217]. Moreover, Cus B, E, and I demonstrate anti-platelet and anti-thrombotic effects by disrupting cytoskeletal dynamics and integrin function [218]. CuB has been reported to down-regulate TNF receptor 1 (TNF-R1), leading to inhibition of expression of the intracellular adhesion molecule-1 (ICAM-1) and suppression of the NF-κB signaling pathway, thereby attenuating inflammatory processes [219]. These multifaceted actions highlight CuB as a promising candidate for therapeutic interventions by targeting inflammation-related disorders and ischemic injuries.

CuB exhibits potential as an anti-cancer agent across various types of cancer. In pancreatic cancer, CuB induces apoptosis both in vitro and in vivo, highlighting its role in cancer immunotherapy through inhibition of the JAK/STAT3 pathway [220]. Furthermore, the diverse anticancer effects of CuB include the reduction of tumor invasiveness, suppression of metastasis-promoting genes, and inhibition of proliferation, invasion, and migration of tumor cells. Many of these effects reflect the ability of CuB to target the EGFR/STAT3/AKT signaling pathway and inhibit the EMT, ultimately inducing apoptosis and obstruction of the critical STAT3-regulated signaling pathways [221].

CuB exhibits promising antitumor effects across various cancer types through distinct mechanisms. In liver CSCs, CuB has been reported to inhibit the JAK2/STAT3 signaling pathway, targeting a crucial pathway involved in cancer stemness [222]. Moreover, CuB demonstrates significant therapeutic potential in NSCLC by inhibiting DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), highlighting its role in epigenetic regulation and cancer cell modulation [223].

Interestingly, in vivo studies conducted in our laboratory demonstrated the effectiveness of CuB in attenuating tumor growth in a NOD-SCID murine model of human melanoma through the inhibition of MEK1/2 and ERK1/2 signaling pathways. Our study also confirmed the pharmacological safety of the compound in Swiss albino mice [224].

Alkaloids

The term "alkaloid" originates from "alkali", suggesting an "alkali-like" nature inherent to these compounds. Alkaloids comprise a class of nitrogen-containing compounds found naturally, often derived from amino acids [225]. Organisms synthesize alkaloids as secondary metabolites primarily for defense, leading to their classification into five types based on the structural positioning of nitrogen: true alkaloids, proto-alkaloids, polyamine alkaloids, peptide and cyclopeptide alkaloids, and pseudoalkaloids [226]. However, the classification of alkaloids lacks a standardized system due to overlapping definitions. Numerous alkaloids extracted from various plants and organisms have been utilized for their pharmacological properties in treating various diseases [227]. Alkaloids demonstrate diverse activities, including anti-cancer, antiviral, analgesic, and anti-inflammatory effects across a spectrum of health conditions [228]. Particularly, cancer, a prevalent ailment in the modern era, has been a focus of research while exploring the utility of alkaloids in treatment [229]. Published studies that delve into the exploration of alkaloids for cancer therapy have led to the discovery of several valuable alkaloids as effective drugs that target selected types of cancer [230, 231].

Alkaloids are classified into different groups based on their structural characteristics. Proto-alkaloids are a subset of plant metabolites characterized by nitrogen atoms derived from amino acid residues, typically in non-cyclic skeletons, and are often derived from tryptophan, tyrosine, or phenylalanine [232]. A coumarin-alkaloid conjugate is a hybrid molecule that combines the structural features of coumarins and alkaloids, leveraging the unique properties of both classes of compounds [233]. Coumarin, a benzopyrone phenolic compound, is essential for life processes in plants, such as photosynthesis, hormone regulation, and respiration. Indole alkaloids, characterized by their pentacyclic and pyrrole rings with a basic nitrogen atom, are the largest category of alkaloids and are widely distributed among plant families [234]. Being clinically significant for their anticancer properties, indole alkaloids like vinblastine and vincristine are used in chemotherapy. Quinoline, a benzopyridine organic molecule, forms the basis of various phytochemicals such as isoquinoline, benzylisoquinoline, and aporphine alkaloids, which have been demonstrated to have antineoplastic effects [235]. Steroidal alkaloids, the derivatives of plant steroids with one or more nitrogen atoms in their heterocyclic rings, possess the biological properties of both alkaloids and steroids, providing protection against environmental threats to plants [236].

Tryptanthrin

Tryptanthrin (indolo[2,1-b]quinazolin-6,12-dione) is an alkaloid possessing an indolo[2,1-b]quinazoline core with various pharmacological properties, including anti-tumor, anti-inflammatory, and anti-bacterial activities. The name tryptanthrin originated from the fact that it was initially isolated from *Candida lipolytica*, a type of bacteria that grows primarily on *L*-tryptophan [237]. In addition to *Candida lipolytica*, other sources of tryptanthrin include fungi like *Schizophyllum commune* and *Leucopaxillus cerealis*, as well as plants like *Couroupita guianensis*, *Wrightia tinctoria*, *Strobilanthes cusia*, *Polygonum tinctorium*, and *Isatis tinctoria* [238–243].

Tryptanthrin exhibits remarkable anti-inflammatory properties across a spectrum of conditions. In LPS-treated BV-2 microglia cells, tryptanthrin has been found to reduce pro-inflammatory cytokine levels through modulating NF- κ B and Nrf2/heme oxygenase-1 (HO-1) pathways, effectively mitigating inflammation in a mouse model of edema [244, 245]. Studies indicate that tryptanthrin alleviates rheumatoid arthritis by reducing proinflammatory cytokine expression and collagen-induced arthritis by down-regulating MMP-3 and IL-6 [246]. The wound healing efficacy of tryptanthrin has been demonstrated in a mouse excisional wound model, where tryptanthrin accelerated the wound healing response by lowering VEGF and MMP-9 levels [247].

Tryptanthrin ameliorates psoriasis by modulating the levels and activity of inflammatory mediators that target T helper 17 (Th17). These include IL-6, IL-8, S100A9 peptide, C-C motif chemokine ligand 20 (CCL20) chemokine, TNF- α , and IL-1 β [248]. Furthermore, tryptanthrin displays promising results against neuroinflammation by reducing the levels of pro-inflammatory cytokines, iNOS, and COX-2 levels in LPS-induced neuroinflammation through inhibition of the TLR4-myeloid differentiation primary response gene 88 (MyD88)- and NF- κ B-dependent pathways [249]. It is suggested that tryptanthrin guards the liver tissue by down-regulating apoptotic processes, lowering inflammatory cell infiltration, and stimulating the AMPK and p38 pathways [250].

Tryptanthrin has been found to boost anti-inflammatory factors and reduce pro-inflammatory markers in HMC-1 cells triggered by atopic dermatitis [251]. It also diminishes leukotriene production, modulates the subcellular localization of 5-LOX, and decreases the levels of its products, thereby alleviating inflammation in pleurisy [252]. Moreover, tryptanthrin significantly mitigates inflammation in dextran sodium sulfate-induced colitis, ensuring 100% survival in treated animals [242].

Tryptanthrin demonstrates potent anti-tumor actions by altering the levels of key proteins involved in cell growth and survival while inducing cell cycle arrest, apoptosis, and autophagy in cancer cells. Additionally, it has been shown to modulate the inflammatory tumor microenvironment, further contributing to its anti-tumor effects [253].

In vitro studies using MCF-7 cells have revealed that tryptanthrin inhibits cell proliferation, migration, and invasion while up-regulating E-cadherin and down-regulating MMP-2 and SNAIL [254]. Another derivative of tryptanthrin, termed benzo[b]tryptanthrin, exhibits potent inhibitory activity against multidrug resistance protein 1 (MDR1) in adriamycin-resistant breast cancer cells [255]. By activating p53 and controlling the TRAIL/death receptors (DRs) pathway, tryptanthrin induces apoptosis in lung cancer cells [256]. Tryptanthrin has been shown to have potent anti-tumor effects against HCC cells, causing S-phase arrest by down-regulating cyclin A1, B1, CDK2, and p-Cdc2, and inducing caspase-dependent apoptosis. It also regulates signaling targets and protects liver cells from oxidative injury [253]. Studies using the human chronic myeloid leukemia cell line K562 suggest that tryptanthrin inhibits the proliferation of leukemia cells and induces apoptosis in these cells through the up-regulation of cytosolic cytochrome-c, BAX, and activated caspase-3 while down-regulating Bcl-2, mitochondrial cytochrome-c, and pro-caspase-3 [257].

Studies from our laboratory have revealed that tryptanthrin from *Wrightia tinctoria* exhibits potent anti-tumor activity against malignant melanoma (A375) cells by targeting key molecules including BRAF, Wnt/ β -catenin, AKT, and NF- κ B pathways that converge on MITF-M. Furthermore, through preclinical investigations, we have demonstrated that tryptanthrin significantly reduces malignant melanoma growth in mice insert [258]. Additionally, our research has extended to explore the anti-tumor effects of tryptanthrin on non-melanoma skin cancer (NMSC) in mouse models. Here, we observed that tryptanthrin inhibits NMSC by inactivating ERK1/2 and p38 regulated pathways, resulting in the suppression of c-Myc and cyclin-D1 expression while promoting β -catenin activity [259].

Cepharanthine

Cepharanthine, derived from *Stephania* tubers, exhibits a variety of pharmacological effects, including antioxidant, anti-inflammatory, immunomodulatory, antitumoral, and antiviral activities [260]. Its interaction with the voltage-dependent anion channel (VDAC) results in voltage-independent channel narrowing, leading to dose-dependent cytotoxicity by altering transport between mitochondria and cytoplasm [261]. Cepharanthine boosts apoptosis in glioma and neuronal cells via ROS and alters mitochondria-to-cytoplasm transport, showcasing diverse medicinal properties, including pathway inhibition, immunomodulation, and antiviral activity against SARS-CoV-2, with over 70 years of clinical use [262]. Additionally, cepharanthine shows promise in treating HCC and alleviating ulcerative colitis by modulating the levels of pro-inflammatory cytokines as well as the gut microbiota [263, 264]. Additionally, cepharanthine has been reported to hinder the release of pro-inflammatory cytokines and the expression of aconitate decarboxylase 1 (ACOD1) in macrophages, reducing macrophage infiltration and ACOD1 levels in

colon tissue [265]. Furthermore, cepharanthine diminishes the viability and promotes apoptosis of myofibroblasts while suppressing the expression of myofibroblast markers. These findings suggest that cepharanthine holds promise as an anti-inflammatory agent for a range of diseases [34].

Cepharanthine also exhibits potent anti-cancer effects against a range of cancers, including HCC, CRC, leukemia, ovarian cancer, and gastric cancer [266]. Its mechanism of action involves the induction of apoptosis, reduction of cell viability, and modulation of critical signaling pathways implicated in cancer progression. Some of its targets within cells include the Bcl-2 family proteins, PARP cleavage, ERK, STAT3, and AKT. The efficacy of cepharanthine extends to both p53 wild-type and mutant cancer cells, suggesting potential utility in treating CRC harboring mutant p53, often resistant to conventional chemotherapy [260]. In liver cancer, cepharanthine was found to inhibit cellular proliferation and invasion, promote apoptosis, and suppress the hedgehog/glioma associated oncogene homolog 1 (Gli1) and Wnt/ β -catenin signaling pathways [267]. Additionally, it is cytotoxic to NSCLC cells through the induction of apoptosis, generation of ROS, and modulation of STAT3, PI3K/AKT, and MAPK/ERK signaling pathways [266].

Oxysophocarpine

Oxysophocarpine (OSP) serves as a prominent quinolizidine natural alkaloid present in leguminous plants such as *Sophora viciifolia* Hance [268], *Sophora alopecuroides* [269], *Sophora flavescens* Ait [270], and other species within the *Robinia* genus [271]. It is a constituent of traditional Chinese medicine, notably found in compound Kushen injection (CKI), utilized for various ailments, including several types of cancer [272]. OSP demonstrates diverse pharmacological properties, including analgesic effects, anti-inflammatory activity, antitumor properties, neuroprotective effects, and antiviral activity [268, 273–275].

OSP demonstrates remarkable anti-inflammatory effects across various disease models. It effectively attenuates inflammation by inhibiting neutrophil recruitment to lesions and reducing levels of key proinflammatory cytokines and chemokines, including TNF-α, IL-1β, IL-6, macrophage inflammatory protein 2 (MIP-2), granulocyte colony stimulating factor (G-CSF), and KC, in tuberculosis-associated inflammation [272]. Moreover, it mitigates inflammation in ulcerative colitis by targeting oxidative stress-related factors such as PGE2, myeloperoxidase (MPO), and superoxide dismutase (SOD), along with inflammationassociated factors like IL-6, TNF- α , and IL-1 β . These effects are mediated through TNF-R-associated factor 6 (TRAF6) down-regulation and NF-κB phosphorylation [268]. In neuronal inflammation, OSP was found to modulate the expression of inflammatory markers including TNF-α, IL-1β, pERK1/2, p-JNK1/2, and p-p38 MAPK [273]. It also reduces carrageenan-induced inflammation in mice by targeting the ERK1/2-COX-2-PGE2 signaling pathway, leading to neutrophil removal and reduced pain perception, further highlighting its broad anti-inflammatory actions. Sophocarpine has been found to alleviate inflammation induced by various agents (e.g., hot plate and xylene) in mice by down-regulating proinflammatory cytokines such as IL-1β, IL-6, and PGE2, and by lowering serum NO levels [276]. Moreover, OSP significantly reduces inflammation in BV-2 microglia under conditions of oxygen-glucose deprivation/reperfusion (OGD/R) by decreasing the expression levels of COX-2, NO synthase, and various inflammatory mediators, while also preventing microglial cell apoptosis [277].

Studies in HCC cell lines, including HepG2 and Hepa1-6, suggest that OSP inhibits cell proliferation and migration while promoting apoptosis. Additionally, it enhances the responsiveness of HCC cells to CD8+ T-cell immunotherapy by modulating IL-6-mediated JAK2/STAT3 signaling [278]. It also acts as an anti-tumor agent against oral squamous cell carcinoma by suppressing cell proliferation and metastasis, mediated by the down-regulation of Nrf2 and the *HO* gene [279].

Berberine

Berberine is an isoquinoline quaternary alkaloid (or a 5,6-dihydrodibenzo[a,g]quinolizinium derivative) extracted from various medicinal plants such as *Hydrastis canadensis*, *Berberis aristata*, *Coptis chinensis*, *Coptis rhizome*, *Coptis japonica*, *Phellodendron amurense*, and *Phellodendron chinense* Schneid [280]. Traditionally, it has been utilized as an antidiarrheal, antibacterial, antifungal, and antiprotozoal agent [281]. However, recent studies have highlighted its potential benefits in treating neurodegenerative

diseases, primarily due to its strong antioxidant properties. Berberine, an isoquinoline alkaloid, is found in multiple plants, including species from the *Coptis* and *Berberis* genera [282].

Berberine induces apoptosis in cancer cells by activating various pathways, such as caspase-mediated pathways, mitochondrial pathways, and PI3K/AKT signaling inhibition. It can inhibit the proliferation of cancer cells by affecting cell cycle progression, particularly by arresting cells in the G1 or G2/M phases. Berberine has been reported to inhibit angiogenesis, the process by which new blood vessels are formed to supply nutrients to tumors, thereby suppressing tumor growth [283].

Berberine also exhibits potent anti-inflammatory effects, which are crucial in cancer therapy and other inflammatory conditions. Berberine can suppress the production and release of pro-inflammatory cytokines and mediators, such as TNF- α , IL-6, and COX-2. It inhibits the activation of NF- κ B, a key transcription factor involved in the regulation of inflammatory responses, and can modulate immune responses, activating anti-inflammatory pathways and regulating inflammatory cascades [283].

Evodiamine

Evodiamine is a quinolone alkaloid with a tetracyclic structure containing both indole and quinazoline ring systems. Its molecular structure includes hydroxyl, methoxy, and carbonyl groups, contributing to its pharmacological activities [284]. It is the primary component extracted from the fruit of *Evodia rutaecarpa*. It has been demonstrated to have multiple biological effects, such as stimulating testosterone and catecholamine secretion while exhibiting antinociceptive, anti-inflammatory, anti-obesity, vasodilatory, thermoregulatory, and uterotonic properties [285]. Nanocarriers can potentially increase the therapeutic efficacy of evodiamine in cancer therapy while minimizing adverse effects. Numerous studies have focused on developing smart nanocarriers to overcome evodiamine's limitations [286].

Evodiamine has been demonstrated to have significant anti-tumor properties by inhibiting the proliferation of various cancer cell lines, including cervical, colon, lung, melanoma, leukemic T-lymphocyte, prostate, and breast cancer cells. One key mechanism involves arresting cell cycle progression at the G2/M phase through the activation of Cdc2/cyclin B. Additionally, evodiamine induces apoptosis in tumor cells through multiple pathways. The PI3K/AKT and ERK signaling pathways play crucial roles in the apoptotic response of tumor cells to evodiamine [287].

Evodiamine induces apoptosis by modulating NF- κ B activation, which inhibits NF- κ B-regulated gene products such as cyclin D1, X linked inhibitor of apoptosis protein (XIAP), Bcl-2, and Bcl-Xl. Other studies have shown that evodiamine increases the expression of the apoptosis inducer, BAX, and decreases the expression of the apoptosis suppressor, Bcl-2, thereby inducing apoptosis via the caspase pathway. ROS and NO generation also regulate p53, p21, protein tyrosine kinases (PTK), and other signaling proteins involved in evodiamine-induced apoptosis [288].

Miscellaneous compounds

Organosulfur compounds are renowned for their beneficial effects, which include anti-inflammatory, antioxidant, and anti-cancer properties [289]. These compounds are abundant in foods such as garlic, onion, asparagus, and cruciferous vegetables like broccoli, cauliflower, and cabbage [290].

Animal studies and epidemiological research suggest that organosulfur compounds can reduce the risk of CRC by inducing mitotic arrest and apoptosis [291]. Specific sulfur-containing compounds like allicin, ajoene, and isothiocyanates exhibit antibacterial and antifungal activities [292]. One well-studied organosulfur compound is sulforaphane, classified as an isothiocyanate, which shows promising chemopreventive properties. Sulforaphane induces phase I and II detoxification enzymes and plays a role in preventing carcinogenesis. It also exerts anti-tumor effects during the post-initiation phase [293].

Pectin, a natural polysaccharide derived from plants like citrus fruits and apples, consists of a linear chain of α -(1-4) linked D-galacturonic acid residues [294]. Low-molecular weight citrus pectin has emerged as a promising anti-cancer agent by exerting multiple beneficial effects [295]. It has been reported that pectin suppresses cancer cell adhesion, aggregation, and metastasis while also inhibiting the activity of the

premetastatic protein galectin-3 (GAL-3). Additionally, citrus pectin promotes caspase-mediated apoptosis and inhibits tumor cell growth, highlighting its potential in cancer therapy [295, 296].

Plant-based non-digestible carbohydrates like pectin lower the risk for CRC by inhibiting GAL-3 protein expression, which augments apoptosis and inhibits cancer cell migration [295]. Similarly, ferulic acid, a bioactive component found in rice bran, exhibits anti-inflammatory, anti-diabetic, anti-cancer, and antioxidant activities [297]. Rice bran itself demonstrates notable antitumor activities by modulating various biochemical pathways, including the inhibition of oxidative stress and the induction of apoptosis [298].

Thiazole-based peptides from marine sources are notable for their distinctive structures and varied pharmacological effects, including inducing apoptosis in cancer cells, inhibiting their proliferation, and modulating immune responses by reducing inflammation by inhibiting pro-inflammatory cytokines and enzymes [299]. *Chenopodium album*, a traditional Indian medicinal plant, is widely used for treating diabetes, digestive issues, and skin diseases. The plant extract exhibited significant α -glucosidase inhibitory activity and strong antioxidant properties, indicating its potential to lower blood glucose levels and reduce diabetic oxidative stress [300]. Allicin, the sulphur containing compound produced by garlic when it's crushed, exhibits a range of biological activities, such as inhibiting cancer cell growth, inducing apoptosis, protecting cells from oxidative damage, reducing inflammation, and modulating the immune system [301].

Limitations of phytochemicals

Phytochemicals, despite their significant anticancer potential and therapeutic benefits, face several limitations that hinder their widespread clinical application. Some of the limitations include poor bioavailability, solubility, hydrophobicity, and restricted therapeutic potential, leading to reduced efficacy [302]. Apart from these, obstacles such as toxicity, high production cost, inadequate availability of raw materials, and ineffective regulatory system impede further barriers to the commercial utilization of plant-based bioactive compounds [303].

Even modern drug delivery systems, including nano drug delivery systems, encounter several limitations despite their promising advantages. A few of the challenges include limited solubility, stability of the natural products when administrated orally, short durations of effectiveness, non-specific targeting that hinders the potential of the system, and poor bioavailability. Apart from these, issues like poor patient compliance, dermal discomfort, and pain associated with parenteral routes further restrict the efficacy of protein based drug delivery systems [304].

Even though nanotechnology offers solutions to improve the pharmacological and therapeutic qualities of conventional medicines, strict regulatory standards are necessary to address drawbacks and ensure the safe and effective delivery of drugs at the cellular levels. Despite these limitations, ongoing advancements in phytochemical and nano drug delivery systems continue to demonstrate promising strategies to overcome challenges and transform the field of medicine [305].

Conclusions

The present review underscores the substantial role of diverse phytochemicals in exerting anti-cancer and anti-inflammatory effects. Our comprehensive analysis has illuminated the multifaceted mechanisms through which these natural compounds exhibit therapeutic effects in cancer and inflammatory diseases. By targeting pivotal signaling pathways and key effector proteins such as MAPK, PI3K/AKT/mTOR, JAK/STAT, Wnt, and NF-kB (Figure 3), phytochemicals actively modulate gene expression and orchestrate cellular processes, thus offering promising avenues for the development of novel therapeutic agents. The increasing recognition of their varied biological activities has sparked significant interest in their potential application in cancer therapy and anti-inflammatory treatment. As our understanding of the intricate molecular mechanisms underlying tumor growth and inflammation continues to evolve, there is a burgeoning optimism regarding the integration of phytochemicals into comprehensive prevention and treatment strategies. Future research endeavors are anticipated to prioritize the development of targeted

therapies utilizing specific phytochemicals or their derivatives. Furthermore, the prospect of nutritional interventions tailored to individual genetic and metabolic profiles may soon be within reach. Phytochemicals, whether employed individually or in combination with conventional chemotherapeutic drugs, exhibit promise in enhancing therapeutic efficacy and mitigating challenges such as chemoresistance and inflammation. Moreover, the exploration of innovative drug delivery systems aimed at augmenting phytochemical bioavailability and tissue specificity holds significant promise. Ultimately, the future trajectory of phytochemicals in cancer therapy and inflammatory disorders represents an integrative and complementary approach to conventional therapeutic modalities, poised to make substantial contributions to disease prevention and management.




Figure 3. The pivotal pathways that are targeted by the major phytochemicals (ChemDraw has been used to draw some parts of this figure). MAPK: mitogen-activated protein kinase; JAK: Janus kinase; STAT: signal transducer and activator of transcription; AKT: protein kinase B; NF-κB: nuclear factor kappa B; ERK: extracellular signal regulated kinase; IκB: inhibitor of NF-κB; EMT: epithelial-mesenchymal transition; Wnt: wingless-related integration site; Raf: rapidly accelerated fibrosarcoma; TCF: T cell factor; AXIN: axis inhibition protein; GSK3β: glycogen synthase kinase 3 beta; PIP-2: phosphatidylinositol 4,5-bisphosphate; PTEN: phosphate and tensin homolog; IKK: inhibitor kappa B kinase; PIP-3: phosphatidylinositol 3,4,5-triphosphate

Future prospective

The exploration of phytochemicals has revealed their promising potential in cancer therapy and inflammation management. Cutting-edge techniques such as genomics, proteomics, and metabolomics can provide detailed insights into the mechanisms of action of these compounds, enabling the development of more targeted and effective therapies. The integration of nanotechnology with phytochemical research can enhance the bioavailability, stability, and targeting efficiency of phytochemicals, overcoming traditional limitations such as poor solubility and rapid metabolism. Investigating the synergistic effects of phytochemicals with conventional anti-cancer and anti-inflammatory drugs could lead to the development of combination therapies that are more effective and reduce side effects. The synthesis and evaluation of novel derivatives and analogs of flavonoids, saponins, terpenoids, and alkaloids can lead to compounds with enhanced activity. The application of phytochemicals in personalized medicine holds significant promise in treatment strategies. Well-designed clinical trials are needed to validate the therapeutic potential of phytochemicals and to establish standardized treatment protocols. Collaboration between researchers, clinicians, and pharmaceutical companies will be key to advancing this field. In conclusion, the future of

phytochemicals in cancer and inflammation therapy is promising, with numerous avenues for research and development. By tackling the challenges, we can unlock the full potential of these natural compounds, leading to improved patient outcomes and significant advancements in the field of medicine.

Abbreviations

15-LOX: 15-lipoxygenase

AKT: protein kinase B

BAX: B-cell lymphoma 2-associated protein x

Bcl-2: B-cell lymphoma 2

Cdc42: cell division control protein 42

COX: cyclooxygenase CRC: colorectal cancer CuB: cucurbitacin B

DETS: 3,5-dihydroxy-4-ethyl-trans-stilbene

EGCG: epigallocatechin 3-gallate

EMT: epithelial-mesenchymal transition ERK: extracellular signal regulated kinase

ER-α: estrogen receptor-alpha

FAK: focal adhesion kinase

FDA: Food and Drug Administration

FST: fisetin

HCC: hepatocellular carcinoma

IL-1β: interleukin 1β

JAKs: Janus kinases

JNK: C-Jun N-terminal kinase

LPS: lipopolysaccharide

MAPKs: mitogen-activated protein kinases

MMP-9: matrix metalloproteinase-9

NF-κB: nuclear factor kappa B

NO: nitric oxide

NSCLC: non-small cell lung cancer

OSP: oxysophocarpine PGE2: prostaglandin E2

ROS: reactive oxygen species

RSV: resveratrol

STAT3: signal transducer and activator of transcription 3

TLR4: Toll-like receptor 4

TNF- α : tumor necrosis factor-alpha

TSAIII: timosaponin A-III

UA: ursolic acid

Utt-B: uttroside B

VEGF: vascular endothelial growth factor Wnt: wingless-related integration site

Declarations

Acknowledgments

We acknowledge Council of Scientific & Industrial Research (CSIR) - India for the funding. We thank Dr Kavitha A. K. for the help rendered in generating high resolution images of chemical structures of the compounds in the manuscript.

Author contributions

SCS, MPJ, and TPR: Investigation, Visualization, Writing—original draft. SUA and CKK: Visualization. AA: Writing—original draft. NI: Writing—review & editing. RJA: Writing—review & editing, Supervision, Funding acquisition. The final version of the manuscript was read and approved by all authors.

Conflicts of interest

Noah Isakov who is the Editorial Board Member and Guest Editor of *Exploration of Drug Science*, and Ruby John Anto who is the Guest Editor of *Exploration of Drug Science*, had no involvement in the decision-making or the review process of this manuscript. The other authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by Council of Scientific & Industrial Research (CSIR) – India [Grant No. CSIR – (60(0124)/20/EMR-II)]. The data collection for this manuscript was facilitated through the support of the CSIR India. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.

Copyright

© The Author(s) 2024.

References

- 1. Jang JH, Lee TJ. Mechanisms of Phytochemicals in Anti-Inflammatory and Anti-Cancer. Int J Mol Sci. 2023;24:7863. [DOI] [PubMed] [PMC]
- 2. Patra AK. An Overview of Antimicrobial Properties of Different Classes of Phytochemicals. In: Patra AK, editor. Dietary Phytochemicals and Microbes. Dordrecht: Springer Netherlands; 2012. pp. 1–32. [DOI]

- 3. Ramawat KG, Dass S, Mathur M. The Chemical Diversity of Bioactive Molecules and Therapeutic Potential of Medicinal Plants. In: Ramawat KG, editor. Herbal Drugs: Ethnomedicine to Modern Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. pp. 7–32. [DOI]
- 4. Cristani M, Micale N. Bioactive Compounds from Medicinal Plants as Potential Adjuvants in the Treatment of Mild Acne Vulgaris. Molecules. 2024;29:2394. [DOI] [PubMed] [PMC]
- 5. Rais J, Jafri A, Siddiqui S, Tripathi M, Arshad M. Phytochemicals in the treatment of ovarian cancer. Front Biosci (Elite Ed). 2017;9:67–75. [DOI] [PubMed]
- 6. Ahmed AU. An overview of inflammation: mechanism and consequences. Front Biol. 2011;6:274–81. [DOI]
- 7. Schmid-Schönbein GW. Analysis of inflammation. Annu Rev Biomed Eng. 2006;8:93–151. [DOI] [PubMed]
- 8. Piotrowski I, Kulcenty K, Suchorska W. Interplay between inflammation and cancer. Rep Pract Oncol Radiother. 2020;25:422–7. [DOI] [PubMed] [PMC]
- 9. Yuan R, Huang L, Du LJ, Feng JF, Li J, Luo YY, et al. Dihydrotanshinone exhibits an anti-inflammatory effect *in vitro* and *in vivo* through blocking TLR4 dimerization. Pharmacol Res. 2019;142:102–14. [DOI] [PubMed]
- 10. Nisar A, Jagtap S, Vyavahare S, Deshpande M, Harsulkar A, Ranjekar P, et al. Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice. Front Pharmacol. 2023;14:1177050. [DOI] [PubMed] [PMC]
- Yu C, Wang D, Yang Z, Wang T. Pharmacological Effects of Polyphenol Phytochemicals on the Intestinal Inflammation via Targeting TLR4/NF-κB Signaling Pathway. Int J Mol Sci. 2022;23:6939.[DOI] [PubMed] [PMC]
- 12. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. [DOI] [PubMed]
- 13. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. [DOI] [PubMed]
- 14. Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4:127–9. [DOI]
- 15. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27–36. [DOI] [PubMed] [PMC]
- 16. Liu S, Li L, Ren D. Anti-Cancer Potential of Phytochemicals: The Regulation of the Epithelial-Mesenchymal Transition. Molecules. 2023;28:5069. [DOI] [PubMed] [PMC]
- 17. Rajasekar J, Perumal MK, Vallikannan B. A critical review on anti-angiogenic property of phytochemicals. J Nutr Biochem. 2019;71:1–15. [DOI] [PubMed]
- 18. Chimento A, De Luca A, D'Amico M, De Amicis F, Pezzi V. The Involvement of Natural Polyphenols in Molecular Mechanisms Inducing Apoptosis in Tumor Cells: A Promising Adjuvant in Cancer Therapy. Int J Mol Sci. 2023;24:1680. [DOI] [PubMed] [PMC]
- 19. Riaz A, Zara R, Bushra G, Kanwal N, Sadiqa A, Shareef F, et al. Chapter 8 Cancer metabolism regulation by phytonutrients. In: Khan H, Akkol EK, Daglia M, editors. The Role of Phytonutrients in Metabolic Disorders. Academic Press; 2022. pp. 237–90. [D01]
- 20. Bathaie SZ, Faridi N, Nasimian A, Heidarzadeh H, Tamanoi F. How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth? Enzymes. 2015;37:1–42. [DOI] [PubMed]
- 21. Rabizadeh F, Mirian MS, Doosti R, Kiani-Anbouhi R, Eftekhari E. Phytochemical Classification of Medicinal Plants Used in the Treatment of Kidney Disease Based on Traditional Persian Medicine. Evid Based Complement Alternat Med. 2022;2022:8022599. [DOI] [PubMed] [PMC]
- 22. Bruce SO. Secondary Metabolites from Natural Products. In: Vijayakumar R, Raja SSS, editors. Secondary Metabolites Trends and Reviews. Rijeka: IntechOpen; 2022. [DOI]

- 23. Asaduzzaman M, Asao T. Introductory Chapter: Phytochemicals and Disease Prevention. In: Asao T, Asaduzzaman M, editors. Phytochemicals Source of Antioxidants and Role in Disease Prevention. Rijeka: IntechOpen; 2018. [DOI]
- 24. Shin SA, Joo BJ, Lee JS, Ryu G, Han M, Kim WY, et al. Phytochemicals as Anti-Inflammatory Agents in Animal Models of Prevalent Inflammatory Diseases. Molecules. 2020;25:5932. [DOI] [PubMed] [PMC]
- 25. Meccariello R, D'Angelo S. Impact of Polyphenolic-Food on Longevity: An Elixir of Life. An Overview. Antioxidants (Basel). 2021;10:507. [DOI] [PubMed] [PMC]
- 26. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med. 2002;113:71–88. [DOI] [PubMed]
- 27. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47. [DOI] [PubMed] [PMC]
- 28. Dias MC, Pinto DCGA, Silva AMS. Plant Flavonoids: Chemical Characteristics and Biological Activity. Molecules. 2021;26:5377. [DOI] [PubMed] [PMC]
- 29. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013;2013:162750. [DOI] [PubMed] [PMC]
- 30. D'Amelia V, Aversano R, Chiaiese P, Carputo D. The antioxidant properties of plant flavonoids: their exploitation by molecular plant breeding. Phytochem Rev. 2018;17:611–25. [DOI]
- 31. Nabavi SM, Šamec D, Tomczyk M, Milella L, Russo D, Habtemariam S, et al. Flavonoid biosynthetic pathways in plants: Versatile targets for metabolic engineering. Biotechnol Adv. 2020;38:107316. [DOI] [PubMed]
- 32. Ullah A, Munir S, Badshah SL, Khan N, Ghani L, Poulson BG, et al. Important Flavonoids and Their Role as a Therapeutic Agent. Molecules. 2020;25:5243. [DOI] [PubMed] [PMC]
- 33. Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as Anticancer Agents. Nutrients. 2020;12:457. [DOI] [PubMed] [PMC]
- 34. Chen G, Li J, Liu H, Zhou H, Liu M, Liang D, et al. Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation. Molecules. 2023;28:753. [DOI] [PubMed] [PMC]
- 35. Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B. Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity. Food Chem. 2022;383:132531. [DOI] [PubMed]
- 36. Hostetler GL, Ralston RA, Schwartz SJ. Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity. Adv Nutr. 2017;8:423–35. [DOI] [PubMed] [PMC]
- 37. Chagas MDSS, Behrens MD, Moragas-Tellis CJ, Penedo GXM, Silva AR, Gonçalves-de-Albuquerque CF. Flavonols and Flavones as Potential anti-Inflammatory, Antioxidant, and Antibacterial Compounds. Oxid Med Cell Longev. 2022;2022:9966750. [DOI] [PubMed] [PMC]
- 38. Mattioli R, Francioso A, Mosca L, Silva P. Anthocyanins: A Comprehensive Review of Their Chemical Properties and Health Effects on Cardiovascular and Neurodegenerative Diseases. Molecules. 2020; 25:3809. [DOI] [PubMed] [PMC]
- 39. Yu J, Bi X, Yu B, Chen D. Isoflavones: Anti-Inflammatory Benefit and Possible Caveats. Nutrients. 2016;8:361. [DOI] [PubMed] [PMC]
- 40. Dziągwa-Becker M, Oleszek M, Zielińska S, Oleszek W. Chalcones—Features, Identification Techniques, Attributes, and Application in Agriculture. Molecules. 2024;29:2247. [DOI] [PubMed] [PMC]
- 41. Choi JK, Kwon OY, Lee SH. Kaempferide Prevents Photoaging of Ultraviolet-B Irradiated NIH-3T3 Cells and Mouse Skin via Regulating the Reactive Oxygen Species-Mediated Signalings. Antioxidants (Basel). 2023;12:11. [DOI] [PubMed] [PMC]

- 42. Tang H, Zeng Q, Ren N, Wei Y, He Q, Chen M, et al. Kaempferide improves oxidative stress and inflammation by inhibiting the TLR4/IκBα/NF-κB pathway in obese mice. Iran J Basic Med Sci. 2021; 24:493–8. [DOI] [PubMed] [PMC]
- 43. Wang D, Zhang X, Li D, Hao W, Meng F, Wang B, et al. Kaempferide Protects against Myocardial Ischemia/Reperfusion Injury through Activation of the PI3K/Akt/GSK-3β Pathway. Mediators Inflamm. 2017;2017:5278218. [DOI] [PubMed] [PMC]
- 44. Nath LR, Gorantla JN, Joseph SM, Antony J, Thankachan S, Menon DB, et al. Kaempferide, the most active among the four flavonoids isolated and characterized from *Chromolaena odorata*, induces apoptosis in cervical cancer cells while being pharmacologically safe. RSC Adv. 2015;5:100912–22. [DOI]
- 45. Imran M, Salehi B, Sharifi-Rad J, Aslam Gondal T, Saeed F, Imran A, et al. Kaempferol: A Key Emphasis to Its Anticancer Potential. Molecules. 2019;24:2277. [DOI] [PubMed] [PMC]
- 46. Chandrababu G, Varkey M, Devan AR, Anjaly MV, Unni AR, Nath LR. Kaempferide exhibits an anticancer effect against hepatocellular carcinoma in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2023;396:2461–7. [DOI] [PubMed]
- 47. Eguchi H, Matsunaga T, Endo S, Ichihara K, Ikari A. Kaempferide Enhances Chemosensitivity of Human Lung Adenocarcinoma A549 Cells Mediated by the Decrease in Phosphorylation of Akt and Claudin-2 Expression. Nutrients. 2020;12:1190. [DOI] [PubMed] [PMC]
- 48. Nath LR, Alex VV, Aiswarya SU, Rayginia TP, Haritha NH, Keerthana CK, et al. Kaempferide induces apoptosis in cervical cancer by attenuating the HPV oncoproteins, E6 and E7. bioRxiv 2023.05.19.541414 [Preprint]. 2023 [cited 2023 May 23]. Available from: http://biorxiv.org/content/early/2023/05/22/2023.05.19.541414.abstract
- 49. Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67:1849–55. [DOI] [PubMed] [PMC]
- 50. Min KJ, Kwon TK. Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. Integr Med Res. 2014;3:16–24. [DOI] [PubMed] [PMC]
- 51. Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di Paola R, Cuzzocrea S. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? Int J Mol Sci. 2020;21:5171. [DOI] [PubMed] [PMC]
- 52. Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013;168:1059–73. [DOI] [PubMed] [PMC]
- 53. Mokra D, Joskova M, Mokry J. Therapeutic Effects of Green Tea Polyphenol (–)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis. Int J Mol Sci. 2023;24:340. [DOI] [PubMed] [PMC]
- 54. Marín V, Burgos V, Pérez R, Maria DA, Pardi P, Paz C. The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment. Int J Mol Sci. 2023;24:10737. [DOI] [PubMed] [PMC]
- 55. Banerjee S, Mandal AKA. Role of epigallocatechin-3- gallate in the regulation of known and novel microRNAs in breast carcinoma cells. Front Genet. 2022;13:995046. [DOI] [PubMed] [PMC]
- 56. Li D, Cao D, Cui Y, Sun Y, Jiang J, Cao X. The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma. Front Pharmacol. 2023;14:1201085. [DOI] [PubMed] [PMC]
- 57. Kang DY, Sp N, Lee JM, Jang KJ. Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells. Biomedicines. 2021;9:297. [DOI] [PubMed] [PMC]
- 58. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (–)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett. 2009;275:86–92. [DOI] [PubMed] [PMC]

- 59. Yeo C, Han DS, Lee HJ, Lee EO. Epigallocatechin-3-Gallate Suppresses Vasculogenic Mimicry through Inhibiting the Twist/VE-Cadherin/AKT Pathway in Human Prostate Cancer PC-3 Cells. Int J Mol Sci. 2020;21:439. [DOI] [PubMed] [PMC]
- 60. Wang Y, Jin SS, Li DT, Jiang XC, Afrasiyab, Khalid A, et al. Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation. Am J Cancer Res. 2023;13:1407–24. [PubMed] [PMC]
- 61. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009;9:31–59. [DOI] [PubMed]
- 62. Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8:634–46. [DOI] [PubMed] [PMC]
- 63. Punia Bangar S, Kajla P, Chaudhary V, Sharma N, Ozogul F. Luteolin: A flavone with myriads of bioactivities and food applications. Food Biosci. 2023;52:102366. [DOI]
- 64. Chen CY, Peng WH, Tsai KD, Hsu SL. Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 2007;81: 1602–14. [DOI] [PubMed] [PMC]
- 65. Gendrisch F, Esser PR, Schempp CM, Wölfle U. Luteolin as a modulator of skin aging and inflammation. Biofactors. 2021;47:170–80. [DOI] [PubMed]
- 66. Mahdiani S, Omidkhoda N, Heidari S, Hayes AW, Karimi G. Protective effect of luteolin against chemical and natural toxicants by targeting NF-κB pathway. Biofactors. 2022;48:744–62. [DOI] [PubMed]
- 67. Shahzadi A, Tariq N, Sonmez H, Waquar S, Zahid A, Javed MA, et al. Potential effect of luteolin, epiafzelechin, and albigenin on rats under cadmium-induced inflammatory insult: *In silico* and *in vivo* approach. Front Chem. 2023;11:1036478. [DOI] [PubMed] [PMC]
- 68. Singh Tuli H, Rath P, Chauhan A, Sak K, Aggarwal D, Choudhary R, et al. Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives. Cancers (Basel). 2022;14:5373. [DOI] [PubMed] [PMC]
- 69. Cai Z, Mao C, Wang Y, Zhu Z, Xu S, Chen D, et al. Research Progress with Luteolin as an Anti-Tumor Agent. Nat Prod Commun. 2022;17:1934578X221133579. [DOI]
- 70. Ye Y, Huang Z, Chen M, Mo Y, Mo Z. Luteolin Potentially Treating Prostate Cancer and COVID-19 Analyzed by the Bioinformatics Approach: Clinical Findings and Drug Targets. Front Endocrinol (Lausanne). 2022;12:802447. [DOI] [PubMed] [PMC]
- 71. Han Y, Xiao Y, Yu L, Chen J, Yang X, Cui H, et al. Advances in the Mechanism of Luteolin against Hepatocellular Carcinoma Based on Bioinformatics and Network Pharmacology. J Cancer. 2023;14: 966–80. [DOI] [PubMed] [PMC]
- 72. Hanchinalmath JV, Londonkar R. Cytotoxic and apoptosis-inducing effect of luteolin isolated from *Feronia limonia* on HepG2 cells. Biolife. 2014;2:1287–92. [DOI]
- 73. Wang C, Li Q, Xiao B, Fang H, Huang B, Huang F, et al. Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells. J Clin Lab Anal. 2021;35: e23677. [DOI] [PubMed] [PMC]
- 74. Wang H, Luo Y, Qiao T, Wu Z, Huang Z. Luteolin sensitizes the antitumor effect of cisplatin in drugresistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. J Ovarian Res. 2018;11:93. [DOI] [PubMed] [PMC]
- 75. Ham S, Kim KH, Kwon TH, Bak Y, Lee DH, Song YS, et al. Luteolin induces intrinsic apoptosis via inhibition of E6/E7 oncogenes and activation of extrinsic and intrinsic signaling pathways in HPV-18-associated cells. Oncol Rep. 2014;31:2683–91. [DOI] [PubMed]
- 76. Grynkiewicz G, Demchuk OM. New Perspectives for Fisetin. Front Chem. 2019;7:697. [DOI] [PubMed] [PMC]

- 77. Solanki R, Srivastav AK, Patel S, Singh SK, Jodha B, Kumar U, et al. Folate conjugated albumin as a targeted nanocarrier for the delivery of fisetin: *in silico* and *in vitro* biological studies. RSC Adv. 2024; 14:7338–49. [DOI] [PubMed] [PMC]
- 78. Rahmani AH, Almatroudi A, Allemailem KS, Khan AA, Almatroodi SA. The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment. Molecules. 2022;27:9009. [DOI] [PubMed] [PMC]
- 79. Pal HC, Sharma S, Strickland LR, Katiyar SK, Ballestas ME, Athar M, et al. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways. PLoS One. 2014;9:e86338. [DOI] [PubMed] [PMC]
- 80. Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancer prevention and treatment. Mol Nutr Food Res. 2016;60:1396–405. [DOI] [PubMed] [PMC]
- 81. Dai J, Mumper RJ. Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules. 2010;15:7313–52. [DOI] [PubMed] [PMC]
- 82. Santos-Sánchez NF, Salas-Coronado R, Hernández-Carlos B, Villanueva-Cañongo C. Shikimic Acid Pathway in Biosynthesis of Phenolic Compounds. In: Soto-Hernández M, García-Mateos R, Palma-Tenango M, editors. Plant Physiological Aspects of Phenolic Compounds. Rijeka: IntechOpen; 2019. [DOI]
- 83. Su X, Zhou D, Li N. Chapter 8 Bioactive stilbenes from plants. In: Atta-ur-Rahman FRS, editor. Studies in Natural Products Chemistry. Elsevier; 2022. pp. 265–403. [DOI]
- 84. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727–47. [DOI] [PubMed]
- 85. Afnan, Saleem A, Akhtar MF, Sharif A, Akhtar B, Siddique R, et al. Anticancer, Cardio-Protective and Anti-Inflammatory Potential of Natural-Sources-Derived Phenolic Acids. Molecules. 2022;27:7286. [DOI] [PubMed] [PMC]
- 86. Nguyen TLA, Bhattacharya D. Antimicrobial Activity of Quercetin: An Approach to Its Mechanistic Principle. Molecules. 2022;27:2494. [DOI] [PubMed] [PMC]
- 87. Hassan MA, Xu T, Tian Y, Zhong Y, Ali FAZ, Yang X, et al. Health benefits and phenolic compounds of *Moringa oleifera* leaves: A comprehensive review. Phytomedicine. 2021;93:153771. [DOI] [PubMed]
- 88. García-Lafuente A, Moro C, Manchón N, Gonzalo-Ruiz A, Villares A, Guillamón E, et al. *In vitro* antiinflammatory activity of phenolic rich extracts from white and red common beans. Food Chem. 2014; 161:216–23. [DOI] [PubMed]
- 89. Singh B, Singh JP, Kaur A, Singh N. Phenolic compounds as beneficial phytochemicals in pomegranate (*Punica granatum* L.) peel: A review. Food Chem. 2018;261:75–86. [DOI] [PubMed]
- 90. Herrera-Rocha KM, Rocha-Guzmán NE, Gallegos-Infante JA, González-Laredo RF, Larrosa-Pérez M, Moreno-Jiménez MR. Phenolic Acids and Flavonoids in Acetonic Extract from Quince (*Cydonia oblonga* Mill.): Nutraceuticals with Antioxidant and Anti-Inflammatory Potential. Molecules. 2022; 27:2462. [DOI] [PubMed] [PMC]
- 91. Ho HH, Chang CS, Ho WC, Liao SY, Wu CH, Wang CJ. Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-κB activity and downregulation of PI3K/AKT/small GTPase signals. Food Chem Toxicol. 2010;48:2508–16. [DOI] [PubMed]
- 92. Orgil O, Schwartz E, Baruch L, Matityahu I, Mahajna J, Amir R. The antioxidative and antiproliferative potential of non-edible organs of the pomegranate fruit and tree. LWT - Food Sci Technol. 2014;58:571–7. [DOI]
- 93. Wang J, Zheng Q, Shi M, Wang H, Fan C, Wang G, et al. Isolation, Identification, Anti-Inflammatory, and In Silico Analysis of New Lignans from the Resin of *Ferula sinkiangensis*. Pharmaceuticals (Basel). 2023;16:1351. [DOI] [PubMed] [PMC]
- 94. Yang Y, Liu Y, Daniyal M, Yu H, Xie Q, Li B, et al. New Lignans from roots of *Kadsura coccinea*. Fitoterapia. 2019;139:104368. [DOI] [PubMed]
- 95. Hu W, Li L, Wang Q, Ye Y, Fan J, Li HX, et al. Dibenzocyclooctadiene lignans from *Kadsura coccinea*. J Asian Nat Prod Res. 2012;14:364–9. [DOI] [PubMed]

- 96. Baumgartner L, Sosa S, Atanasov AG, Bodensieck A, Fakhrudin N, Bauer J, et al. Lignan derivatives from *Krameria lappacea* roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro. J Nat Prod. 2011;74:1779–86. [DOI] [PubMed] [PMC]
- 97. Szopa A, Dziurka M, Warzecha A, Kubica P, Klimek-Szczykutowicz M, Ekiert H. Targeted Lignan Profiling and Anti-Inflammatory Properties of *Schisandra rubriflora* and *Schisandra chinensis* Extracts. Molecules. 2018;23:3103. [DOI] [PubMed] [PMC]
- 98. Mueed A, Deng Z, Korma SA, Shibli S, Jahangir M. Anticancer potential of flaxseed lignans, their metabolites and synthetic counterparts in relation with molecular targets: current challenges and future perspectives. Food Funct. 2023;14:2286–303. [DOI] [PubMed]
- 99. Zamora-Ros R, Sacerdote C, Ricceri F, Weiderpass E, Roswall N, Buckland G, et al. Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Cancer. 2014;111:1870–80. [DOI] [PubMed] [PMC]
- 100. Mikhaevich EI, Sorokin DV, Scherbakov AM. Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin. Res Pharm Sci. 2023;18: 580–91. [DOI] [PubMed] [PMC]
- 101. Wei P, Zhao F, Wang Z, Wang Q, Chai X, Hou G, et al. Sesame (*Sesamum indicum* L.): A Comprehensive Review of Nutritional Value, Phytochemical Composition, Health Benefits, Development of Food, and Industrial Applications. Nutrients. 2022;14:4079. [DOI] [PubMed] [PMC]
- 102. Che N, Li M, Liu X, Cui CA, Gong J, Xuan Y. Macelignan prevents colorectal cancer metastasis by inhibiting M2 macrophage polarization. Phytomedicine. 2024;122:155144. [DOI] [PubMed]
- 103. Di Y, De Silva F, Krol ES, Alcorn J. Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3. Nutr Cancer. 2018;70:306–15. [DOI] [PubMed]
- 104. Owen RW, Mier W, Giacosa A, Hull WE, Spiegelhalder B, Bartsch H. Identification of lignans as major components in the phenolic fraction of olive oil. Clin Chem. 2000;46:976–88. [DOI] [PubMed]
- 105. Duta-Bratu CG, Nitulescu GM, Mihai DP, Olaru OT. Resveratrol and Other Natural Oligomeric Stilbenoid Compounds and Their Therapeutic Applications. Plants (Basel). 2023;12:2935. [DOI] [PubMed] [PMC]
- 106. Hano C, Tungmunnithum D. Plant Polyphenols, More than Just Simple Natural Antioxidants: Oxidative Stress, Aging and Age-Related Diseases. Medicines (Basel). 2020;7:26. [DOI] [PubMed] [PMC]
- 107. Perrone D, Fuggetta MP, Ardito F, Cottarelli A, De Filippis A, Ravagnan G, et al. Resveratrol (3,5,4'-trihydroxystilbene) and its properties in oral diseases. Exp Ther Med. 2017;14:3–9. [DOI] [PubMed] [PMC]
- 108. Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, et al. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines. 2018;6:91. [DOI] [PubMed] [PMC]
- 109. Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa V, Gimeno-Mallench L, et al. Properties of Resveratrol: *In Vitro* and *In Vivo* Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid Med Cell Longev. 2015;2015:837042. [DOI] [PubMed] [PMC]
- 110. Fantacuzzi M, Amoroso R, Carradori S, De Filippis B. Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy. Eur J Med Chem. 2022;233:114242. [DOI] [PubMed]
- 111. Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim Pol. 2019;66:13–21. [DOI] [PubMed]
- 112. Meng X, Zhou J, Zhao CN, Gan RY, Li HB. Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review. Foods. 2020;9:340. [DOI] [PubMed] [PMC]
- 113. Arbo BD, André-Miral C, Nasre-Nasser RG, Schimith LE, Santos MG, Costa-Silva D, et al. Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease. Front Aging Neurosci. 2020;12:103. [DOI] [PubMed] [PMC]

- 114. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets. 2007;6: 168–73. [DOI] [PubMed]
- 115. Cheng G, Xu P, Zhang M, Chen J, Sheng R, Ma Y. Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease. Bioorg Med Chem. 2018;26:5759–65. [DOI] [PubMed]
- 116. Bereswill S, Muñoz M, Fischer A, Plickert R, Haag LM, Otto B, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One. 2010;5: e15099. [DOI] [PubMed] [PMC]
- 117. Yang S, Sun M, Zhang X. Protective Effect of Resveratrol on Knee Osteoarthritis and its Molecular Mechanisms: A Recent Review in Preclinical and Clinical Trials. Front Pharmacol. 2022;13:921003. [DOI] [PubMed] [PMC]
- 118. Fukui M, Yamabe N, Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells *in vitro* and *in vivo*. Eur J Cancer. 2010;46:1882–91. [DOI] [PubMed] [PMC]
- 119. Li J, Chong T, Wang Z, Chen H, Li H, Cao J, et al. A novel anti-cancer effect of resveratrol: reversal of epithelial-mesenchymal transition in prostate cancer cells. Mol Med Rep. 2014;10:1717–24. [DOI] [PubMed] [PMC]
- 120. Najafiyan B, Bokaii Hosseini Z, Esmaelian S, Firuzpour F, Rahimipour Anaraki S, Kalantari L, et al. Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies. Biomed Pharmacother. 2024;172:116207. [DOI] [PubMed]
- 121. Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol. 2005;11:280–4. [DOI] [PubMed] [PMC]
- 122. Vinod BS, Nair HH, Vijayakurup V, Shabna A, Shah S, Krishna A, et al. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. Cell Death Discov. 2015;1:15061. [DOI] [PubMed] [PMC]
- 123. Cotino-Nájera S, Herrera LA, Domínguez-Gómez G, Díaz-Chávez J. Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer. Front Pharmacol. 2023;14:1287505. [DOI] [PubMed] [PMC]
- 124. Nath LR, Kumar SN, Das AA, Nambisan B, Shabna A, Mohandas C, et al. *In Vitro* Evaluation of the Antioxidant, 3,5-Dihydroxy-4-ethyl-trans-stilbene (DETS) Isolated from *Bacillus cereus* as a Potent Candidate against Malignant Melanoma. Front Microbiol. 2016;7:452. [DOI] [PubMed] [PMC]
- 125. Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y, et al. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS One. 2014;9:e102535. [DOI] [PubMed] [PMC]
- 126. Xu XL, Deng SL, Lian ZX, Yu K. Resveratrol Targets a Variety of Oncogenic and Oncosuppressive Signaling for Ovarian Cancer Prevention and Treatment. Antioxidants (Basel). 2021;10:1718. [DOI] [PubMed] [PMC]
- 127. Pouliquen DL, Gall Trošelj K, Anto RJ, Naidu R. Editorial: Curcuminoids: their pleiotropism against hallmarks of cancers. Front Pharmacol. 2023;14:1266793. [DOI] [PubMed] [PMC]
- 128. Ali BH, Marrif H, Noureldayem SA, Bakheit AO, Blunden G. Some Biological Properties of Curcumin: A Review. Nat Prod Commun. 2006;1:1934578X0600100613. [DOI]
- 129. Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014; 19:20091–112. [DOI] [PubMed] [PMC]
- 130. Naujokat C, McKee DL. The "Big Five" Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein. Curr Med Chem. 2021;28:4321–42. [DOI] [PubMed]
- 131. Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Curcumin in Metabolic Health and Disease. Nutrients. 2021;13:4440. [DOI] [PubMed] [PMC]

- 132. Vijayakurup V, Thulasidasan AT, Shankar G M, Retnakumari AP, Nandan CD, Somaraj J, et al. Chitosan Encapsulation Enhances the Bioavailability and Tissue Retention of Curcumin and Improves its Efficacy in Preventing B[a]P-induced Lung Carcinogenesis. Cancer Prev Res (Phila). 2019;12:225–36. [DOI] [PubMed]
- 133. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 2002;23:143–50. [DOI] [PubMed]
- 134. Anto RJ, Maliekal TT, Karunagaran D. L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis. J Biol Chem. 2000;275:15601–4. [DOI] [PubMed]
- 135. Bava SV, Puliyappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem. 2005;280:6301–8. [DOI] [PubMed]
- 136. Yang S, Sun Y, Kapilevich L, Zhang X, Huang Y. Protective effects of curcumin against osteoporosis and its molecular mechanisms: a recent review in preclinical trials. Front Pharmacol. 2023;14: 1249418. [DOI] [PubMed] [PMC]
- 137. Nonn L, Duong D, Peehl DM. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007;28: 1188–96. [DOI] [PubMed]
- 138. Giordano A, Tommonaro G. Curcumin and Cancer. Nutrients. 2019;11:2376. [DOI] [PubMed] [PMC]
- 139. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 1995;94:79–83. [DOI] [PubMed]
- 140. Anto RJ, George J, Babu KV, Rajasekharan KN, Kuttan R. Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. Mutat Res. 1996;370:127–31. [DOI] [PubMed]
- 141. Xu YQ, Chen WR, Tsosie JK, Xie X, Li P, Wan JB, et al. Niosome Encapsulation of Curcumin: Characterization and Cytotoxic Effect on Ovarian Cancer Cells. J Nanomater. 2016;2016:6365295.

 [DOI]
- 142. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12. [DOI] [PubMed] [PMC]
- 143. Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017;6:92. [DOI] [PubMed] [PMC]
- 144. Kwon SJ, Ahn D, Yang HM, Kang HJ, Chung SJ. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2). Molecules. 2021;26:848. [DOI] [PubMed] [PMC]
- 145. Micale N, Molonia MS, Citarella A, Cimino F, Saija A, Cristani M, et al. Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol. Molecules. 2021;26:4665. [DOI] [PubMed] [PMC]
- 146. Sharma K, Kaur R, Kumar S, Saini RK, Sharma S, Pawde SV, et al. Saponins: A concise review on food related aspects, applications and health implications. Food Chem Adv. 2023;2:100191. [DOI]
- 147. Shen X, Shi L, Pan H, Li B, Wu Y, Tu Y. Identification of triterpenoid saponins in flowers of four *Camellia Sinensis* cultivars from Zhejiang province: Differences between cultivars, developmental stages, and tissues. Ind Crops Prod. 2017;95:140–7. [DOI]
- 148. Kitagawa N, Morikawa T, Motai C, Ninomiya K, Okugawa S, Nishida A, et al. The Antiproliferative Effect of Chakasaponins I and II, Floratheasaponin A, and Epigallocatechin 3-*O*-Gallate Isolated from *Camellia sinensis* on Human Digestive Tract Carcinoma Cell Lines. Int J Mol Sci. 2016;17:1979. [DOI] [PubMed] [PMC]

- 149. Zhang Y, Hao R, Chen J, Li S, Huang K, Cao H, et al. Health benefits of saponins and its mechanisms: perspectives from absorption, metabolism, and interaction with gut. Crit Rev Food Sci Nutr. 2024;64: 9311–32. [DOI] [PubMed]
- 150. Khan MI, Karima G, Khan MZ, Shin JH, Kim JD. Therapeutic Effects of Saponins for the Prevention and Treatment of Cancer by Ameliorating Inflammation and Angiogenesis and Inducing Antioxidant and Apoptotic Effects in Human Cells. Int J Mol Sci. 2022;23:10665. [DOI] [PubMed] [PMC]
- 151. Timilsena YP, Phosanam A, Stockmann R. Perspectives on Saponins: Food Functionality and Applications. Int J Mol Sci. 2023;24:13538. [DOI] [PubMed] [PMC]
- 152. Soto-Blanco B. Chapter 12 Herbal glycosides in healthcare. In: Mandal SC, Nayak AK, Dhara AK, editors. Herbal Biomolecules in Healthcare Applications. Academic Press; 2022. pp. 239–82. [DOI]
- 153. Xie J, Zou L, Wu X, Yang L, Li B, Zhang H, et al. In Vitro Structure–Activity Relationships Between Dammarane-Type Saponins Isolated From Panax notoginseng and Their Anti-inflammatory Properties. Nat Prod Commun. 2022;17:1934578X221144572. [DOI]
- 154. Parikh NR, Mandal A, Bhatia D, Siveen KS, Sethi G, Bishayee A. Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives. Phytochem Rev. 2014;13:793–810. [DOI] [PubMed] [PMC]
- 155. Acharya D, Mitaine-Offer AC, Kaushik N, Miyamoto T, Paululat T, Lacaille-Dubois MA. Steroidal saponins from the roots of Chlorophytum borivilianum. Planta Med. 2008;74:PB23. [DOI]
- 156. Nath LR, Gorantla JN, Thulasidasan AK, Vijayakurup V, Shah S, Anwer S, et al. Evaluation of uttroside B, a saponin from *Solanum nigrum* Linn, as a promising chemotherapeutic agent against hepatocellular carcinoma. Sci Rep. 2016;6:36318. [DOI] [PubMed] [PMC]
- 157. Swetha M, Keerthana CK, Rayginia TP, Nath LR, Haritha NH, Shabna A, et al. Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma. Pharmaceuticals (Basel). 2022;15:636. [DOI] [PubMed] [PMC]
- 158. Nath LR, Swetha M, Vijayakurup V, Thangarasu AK, Haritha NH, Shabna A, et al. Blockade of Uttroside B-Induced Autophagic Pro-Survival Signals Augments Its Chemotherapeutic Efficacy Against Hepatocellular Carcinoma. Front Oncol. 2022;12:812598. [DOI] [PubMed] [PMC]
- 159. Liu Z, Cao Y, Guo X, Chen Z. The Potential Role of Timosaponin-AIII in Cancer Prevention and Treatment. Molecules. 2023;28:5500. [DOI] [PubMed] [PMC]
- 160. Lin Y, Zhao WR, Shi WT, Zhang J, Zhang KY, Ding Q, et al. Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From *Anemarrhena asphodeloides* Bunge: A Review. Front Pharmacol. 2020;11:764. [DOI] [PubMed] [PMC]
- 161. Kim KM, Im AR, Park SK, Shin HS, Chae SW. Protective Effects of Timosaponin AIII against UVB-Radiation Induced Inflammation and DNA Injury in Human Epidermal Keratinocytes. Biol Pharm Bull. 2019;42:1524–31. [DOI] [PubMed]
- 162. Kim KM, Im AR, Kim SH, Hyun JW, Chae S. Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and *in vivo* tumor metastasis. Cancer Sci. 2016;107:181–8. [DOI] [PubMed] [PMC]
- 163. Im AR, Seo YK, Cho SH, O KH, Kim KM, Chae S. Clinical evaluation of the safety and efficacy of a timosaponin A-III-based antiwrinkle agent against skin aging. J Cosmet Dermatol. 2020;19:423–36. [DOI] [PubMed] [PMC]
- 164. Zhang M, Qu J, Gao Z, Qi Q, Yin H, Zhu L, et al. Timosaponin AIII Induces G2/M Arrest and Apoptosis in Breast Cancer by Activating the ATM/Chk2 and p38 MAPK Signaling Pathways. Front Pharmacol. 2021;11:601468. [DOI] [PubMed] [PMC]
- 165. Zhang L, Zhang S, Jiang M, Lu L, Ding Y, Ma N, et al. Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer. Int J Nanomedicine. 2021;16:5531–50. [DOI] [PubMed] [PMC]

- 166. Chien HJ, Liu CJ, Ying TH, Wu PJ, Wang JW, Ting YH, et al. Timosaponin AIII Inhibits Migration and Invasion Abilities in Human Cervical Cancer Cells through Inactivation of p38 MAPK-Mediated uPA Expression In Vitro and In Vivo. Cancers (Basel). 2023;15:37. [DOI] [PubMed] [PMC]
- 167. Jung O, Lee J, Lee YJ, Yun JM, Son YJ, Cho JY, et al. Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways. Bioorg Med Chem Lett. 2016;26:3963–7. [DOI] [PubMed]
- 168. Hu QR, Hong H, Zhang ZH, Feng H, Luo T, Li J, et al. Methods on improvements of the poor oral bioavailability of ginsenosides: Pre-processing, structural modification, drug combination, and micro- or nano- delivery system. J Ginseng Res. 2023;47:694–705. [DOI] [PubMed] [PMC]
- 169. Wang Y, Li G, Chen T, Wu W, Yan Z, Li X. Anticancer effect and molecular mechanism of ginsenoside Rg3 in various cancer types. Intell Pharm. 2023;1:52–63. [DOI]
- 170. Liu D, Tian Q, Liu K, Ren F, Liu G, Zhou J, et al. Ginsenoside Rg3 Ameliorates DSS-Induced Colitis by Inhibiting NLRP3 Inflammasome Activation and Regulating Microbial Homeostasis. J Agric Food Chem. 2023;71:3472–83. [DOI] [PubMed]
- 171. Wang J, Zeng L, Zhang Y, Qi W, Wang Z, Tian L, et al. Pharmacological properties, molecular mechanisms and therapeutic potential of ginsenoside Rg3 as an antioxidant and anti-inflammatory agent. Front Pharmacol. 2022;13:975784. [DOI] [PubMed] [PMC]
- 172. Duan X, Cai H, Hu T, Lin L, Zeng L, Wang H, et al. Ginsenoside Rg3 treats acute radiation proctitis through the TLR4/MyD88/NF-κB pathway and regulation of intestinal flora. Front Cell Infect Microbiol. 2023;12:1028576. [DOI] [PubMed] [PMC]
- 173. Hu G, Luo N, Guo Q, Wang D, Peng P, Liu D, et al. Ginsenoside Rg3 Sensitizes Nasopharyngeal Carcinoma Cells to Radiation by Suppressing Epithelial Mesenchymal Transition. Radiat Res. 2023; 199:460–7. [DOI] [PubMed]
- 174. Lv Q, Xia Z, Huang Y, Ruan Z, Wang J, Huang Z. Ginsenoside Rg3 alleviates the migration, invasion, and angiogenesis of lung cancer cells by inhibiting the expressions of cyclooxygenase-2 and vascular endothelial growth factor. Chem Biol Drug Des. 2023;101:937–51. [DOI] [PubMed]
- 175. Ma Z, Zuo Y, Wang W. Ginsenoside Rg3 inhibits renal cell carcinoma cell migration, invasion, colony formation, and tube formation and enhances apoptosis through promoting the DNA demethylation and histone acetylation. J Pharm Pharmacol. 2023;75:76–86. [DOI] [PubMed]
- 176. Peng Y, Zhang R, Kong L, Shen Y, Xu D, Zheng F, et al. Ginsenoside Rg3 inhibits the senescence of prostate stromal cells through down-regulation of interleukin 8 expression. Oncotarget. 2017;8: 64779–92. [DOI] [PubMed] [PMC]
- 177. Mosquera MEG, Jiménez G, Tabernero V, Vinueza-Vaca J, García-Estrada C, Kosalková K, et al. Terpenes and Terpenoids: Building Blocks to Produce Biopolymers. Sustain Chem. 2021;2:467–92. [DOI]
- 178. Bergman ME, Davis B, Phillips MA. Medically Useful Plant Terpenoids: Biosynthesis, Occurrence, and Mechanism of Action. Molecules. 2019;24:3961. [DOI] [PubMed] [PMC]
- 179. Perveen S, Al-Taweel AM, editors. Terpenes and Terpenoids Recent Advances. Rijeka: IntechOpen; 2021. [DOI]
- 180. Khatun A, Rahman M, Rahman MS, Hossain MK, Rashid MA. Terpenoids and phytosteroids isolated from *Commelina benghalensis* Linn. with antioxidant activity. J Basic Clin Physiol Pharmacol. 2020; 31:20180218. [DOI] [PubMed]
- 181. de Passos MS, de Carvalho Junior AR, Boeno SI, das Virgens LdLG, Calixto SD, Ventura TLB, et al. Terpenoids isolated from *Azadirachta indica* roots and biological activities. Rev Bras Farmacogn. 2019;29:40–5. [DOI]
- 182. Wang M. Isolation and Structure Elucidation of Antiproliferative and Antiplasmodial Natural Products from Plants [dissertation]. Blacksburg (VA): Virginia Polytechnic Institute and State University; 2016.

- 183. Del Prado-Audelo ML, Cortés H, Caballero-Florán IH, González-Torres M, Escutia-Guadarrama L, Bernal-Chávez SA, et al. Therapeutic Applications of Terpenes on Inflammatory Diseases. Front Pharmacol. 2021;12:704197. [DOI] [PubMed] [PMC]
- 184. Prakash V. Terpenoids as source of anti-inflammatory compounds. Asian J Pharm Clin Res. 2017;10: 68–76. [DOI]
- 185. Maione F, Cantone V, Pace S, Chini MG, Bisio A, Romussi G, et al. Anti-inflammatory and analgesic activity of carnosol and carnosic acid *in vivo* and *in vitro* and *in silico* analysis of their target interactions. Br J Pharmacol. 2017;174:1497–508. [DOI] [PubMed] [PMC]
- 186. Kim T, Song B, Cho KS, Lee IS. Therapeutic Potential of Volatile Terpenes and Terpenoids from Forests for Inflammatory Diseases. Int J Mol Sci. 2020;21:2187. [DOI] [PubMed] [PMC]
- 187. Kamran S, Sinniah A, Abdulghani MAM, Alshawsh MA. Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review. Cancers (Basel). 2022;14:1100. [DOI] [PubMed] [PMC]
- 188. Kuttan G, Pratheeshkumar P, Manu KA, Kuttan R. Inhibition of tumor progression by naturally occurring terpenoids. Pharm Biol. 2011;49:995–1007. [DOI] [PubMed]
- 189. El-Baba C, Baassiri A, Kiriako G, Dia B, Fadlallah S, Moodad S, et al. Terpenoids' anti-cancer effects: focus on autophagy. Apoptosis. 2021;26:491–511. [DOI] [PubMed]
- 190. Yang YH, Mao JW, Tan XL. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med. 2020;18:890–7. [DOI] [PubMed]
- 191. Vélëz H, Gauchan DP, García-Gil MDR. Taxol and β-tubulins from endophytic fungi isolated from the Himalayan Yew, *Taxus wallichiana* Zucc. Front Microbiol. 2022;13:956855. [DOI] [PubMed] [PMC]
- 192. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99–105. [DOI] [PubMed] [PMC]
- 193. Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30:1705–11. [DOI] [PubMed] [PMC]
- 194. Zhang M, Lotfollahzadeh S, Elzinad N, Yang X, Elsadawi M, Gower A, et al. Alleviating iatrogenic effects of paclitaxel via anti-inflammatory treatment. Res Sq [Preprint]. 2023 [cited 2024 Apr 16]. Available from: https://doi.org/10.21203/rs.3.rs-2487922/v1
- 195. Li Z, Zhao S, Zhang HL, Liu P, Liu FF, Guo YX, et al. Proinflammatory Factors Mediate Paclitaxel-Induced Impairment of Learning and Memory. Mediators Inflamm. 2018;2018:3941840. [DOI] [PubMed] [PMC]
- 196. Faheem M, Khan AU, Saleem MW, Shah FA, Ali F, Khan AW, et al. Neuroprotective Effect of Natural Compounds in Paclitaxel-Induced Chronic Inflammatory Pain. Molecules. 2022;27:4926. [DOI] [PubMed] [PMC]
- 197. Nawara HM, Afify SM, Hassan G, Zahra MH, Seno A, Seno M. Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. Biomedicines. 2021;9:500. [DOI] [PubMed] [PMC]
- 198. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. 2011;30:3139–52. [DOI] [PubMed]
- 199. Bava SV, Sreekanth CN, Thulasidasan AK, Anto NP, Cheriyan VT, Puliyappadamba VT, et al. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol. 2011;43:331–41. [DOI] [PubMed]
- 200. Liu X, Xie C, Li A, Zhang Y, Liu X, Zhou S, et al. BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway. Am J Transl Res. 2019; 11:7255–71. [PubMed] [PMC]

- 201. Yang MH, Baek SH, Ha IJ, Um JY, Ahn KS. Brassinin enhances the anticancer actions of paclitaxel by targeting multiple signaling pathways in colorectal cancer cells. Phytother Res. 2021;35:3875–85. [DOI] [PubMed]
- 202. Woźniak Ł, Skąpska S, Marszałek K. Ursolic Acid—A Pentacyclic Triterpenoid with a Wide Spectrum of Pharmacological Activities. Molecules. 2015;20:20614–41. [DOI] [PubMed] [PMC]
- 203. Kashyap D, Tuli HS, Sharma AK. Ursolic acid (UA): A metabolite with promising therapeutic potential. Life Sci. 2016;146:201–13. [DOI] [PubMed]
- 204. Sandhu SS, Rouz SK, Kumar S, Swamy N, Deshmukh L, Hussain A, et al. Ursolic acid: a pentacyclic triterpenoid that exhibits anticancer therapeutic potential by modulating multiple oncogenic targets. Biotechnol Genet Eng Rev. 2023;39:729–59. [DOI] [PubMed]
- 205. Scherrer EC, Valadares YM, Alves CCS, Carli AP, Fernandes BGR, Carvalho PE, et al. Ursolic Acid Derivatives Down Regulate Inflammatory Mediators. J Braz Chem Soc. 2023;34:1250–61. [DOI]
- 206. Panda SS, Thangaraju M, Lokeshwar BL. Ursolic Acid Analogs as Potential Therapeutics for Cancer. Molecules. 2022;27:8981. [DOI] [PubMed] [PMC]
- 207. Luo F, Zhao J, Liu S, Xue Y, Tang D, Yang J, et al. Ursolic acid augments the chemosensitivity of drugresistant breast cancer cells to doxorubicin by AMPK-mediated mitochondrial dysfunction. Biochem Pharmacol. 2022;205:115278. [DOI] [PubMed]
- 208. Feng XM, Su XL. Anticancer effect of ursolic acid via mitochondria-dependent pathways. Oncol Lett. 2019;17:4761–7. [DOI] [PubMed] [PMC]
- 209. Messina B, Lo Sardo F, Scalera S, Memeo L, Colarossi C, Mare M, et al. Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression. Cell Death Dis. 2023;14:21. [DOI] [PubMed] [PMC]
- 210. Zhao H, Tang S, Tao Q, Ming T, Lei J, Liang Y, et al. Ursolic Acid Suppresses Colorectal Cancer by Down-Regulation of Wnt/β-Catenin Signaling Pathway Activity. J Agric Food Chem. 2023;71: 3981–93. [DOI] [PubMed]
- 211. Junco JJ, Cho J, Mancha A, Malik G, Wei SJ, Kim DJ, et al. Role of AMPK and PPARα in the anti-skin cancer effects of ursolic acid. Mol Carcinog. 2018;57:1698–706. [DOI] [PubMed] [PMC]
- 212. Gao Y, Chen JC, Peng XR, Li ZR, Su HG, Qiu MH. Cucurbitane-Type Triterpene Glycosides from *Momordica charantia* and Their α-Glucosidase Inhibitory Activities. Nat Prod Bioprospect. 2020;10: 153–61. [DOI] [PubMed] [PMC]
- 213. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005;22:386–99. [DOI] [PubMed]
- 214. Dai S, Wang C, Zhao X, Ma C, Fu K, Liu Y, et al. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics. Pharmacol Res. 2023;187:106587. [DOI] [PubMed]
- 215. Li Y, Li Y, Yao Y, Li H, Gao C, Sun C, et al. Potential of cucurbitacin as an anticancer drug. Biomed Pharmacother. 2023;168:115707. [DOI] [PubMed]
- 216. Delgado-Tiburcio EE, Cadena-Iñiguez J, Santiago-Osorio E, Ruiz-Posadas LDM, Castillo-Juárez I, Aguiñiga-Sánchez I, et al. Pharmacokinetics and Biological Activity of Cucurbitacins. Pharmaceuticals (Basel). 2022;15:1325. [DOI] [PubMed] [PMC]
- 217. Chu X, Zhang L, Zhou Y, Fang Q. Cucurbitacin B alleviates cerebral ischemia/reperfusion injury by inhibiting NLRP3 inflammasome-mediated inflammation and reducing oxidative stress. Biosci Biotechnol Biochem. 2022;86:846–54. [DOI] [PubMed]
- 218. Silvestre GFG, de Lucena RP, da Silva Alves H. Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms. Curr Med Chem. 2022;29:3774–89. [DOI] [PubMed]
- 219. Kusagawa E, Okuda C, Yamaguchi R, Nakano K, Miyake Y, Kataoka T. Cucurbitacin B Down-Regulates TNF Receptor 1 Expression and Inhibits the TNF-α-Dependent Nuclear Factor κB Signaling Pathway in Human Lung Adenocarcinoma A549 Cells. Int J Mol Sci. 2022;23:7130. [DOI] [PubMed] [PMC]

- 220. Varela C, Melim C, Neves BG, Sharifi-Rad J, Calina D, Mamurova A, et al. Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms. J Transl Med. 2022;20:630. [DOI] [PubMed] [PMC]
- 221. Ren Y, Huang G, Xue Q, Lv Q, Wu Y, Wu Q, et al. Effect of cucurbitacin on malignant biological behavior of breast cancer cells, and its possible underlying mechanism. Trop J Pharm Res. 2022;21: 297–302. [DOI]
- 222. Wang X, Bai Y, Yan X, Li J, Lin B, Dai L, et al. Cucurbitacin B exhibits antitumor effects on CD133+ HepG2 liver cancer stem cells by inhibiting JAK2/STAT3 signaling pathway. Anticancer Drugs. 2021; 32:548–57. [DOI] [PubMed]
- 223. Shukla S, Khan S, Kumar S, Sinha S, Farhan M, Bora HK, et al. Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis. Cancer Prev Res (Phila). 2015;8:552–62. [DOI] [PubMed]
- 224. Aiswarya SUD, Vikas G, Haritha NH, Liju VB, Shabna A, Swetha M, et al. Cucurbitacin B, Purified and Characterized From the Rhizome of *Corallocarpus epigaeus* Exhibits Anti-Melanoma Potential. Front Oncol. 2022;12:903832. [DOI] [PubMed] [PMC]
- 225. Ferreira MU. Alkaloids in Future Drug Discovery. Molecules. 2022;27:1347. [DOI] [PubMed] [PMC]
- 226. Dostál J. Two Faces of Alkaloids. J Chem Educ. 2000;77:993. [DOI]
- 227. Heinrich M, Mah J, Amirkia V. Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity—An Update and Forward Look. Molecules. 2021;26:1836. [DOI] [PubMed] [PMC]
- 228. Aryal B, Raut BK, Bhattarai S, Bhandari S, Tandan P, Gyawali K, et al. Potential Therapeutic Applications of Plant-Derived Alkaloids against Inflammatory and Neurodegenerative Diseases. Evid Based Complement Alternat Med. 2022;2022:7299778. [DOI] [PubMed] [PMC]
- 229. Habli Z, Toumieh G, Fatfat M, Rahal ON, Gali-Muhtasib H. Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms. Molecules. 2017;22:250. [DOI] [PubMed] [PMC]
- 230. Lu JJ, Bao JL, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med. 2012;2012:485042. [DOI] [PubMed] [PMC]
- 231. Olofinsan K, Abrahamse H, George BP. Therapeutic Role of Alkaloids and Alkaloid Derivatives in Cancer Management. Molecules. 2023;28:5578. [DOI] [PubMed] [PMC]
- 232. Dey P, Kundu A, Kumar A, Gupta M, Lee BM, Bhakta T, et al. Chapter 15 Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids). In: Sanches Silva A, Nabavi SF, Saeedi M, Nabavi SM, editors. Recent Advances in Natural Products Analysis. Elsevier; 2020. pp. 505–67. [DOI]
- 233. Annunziata F, Pinna C, Dallavalle S, Tamborini L, Pinto A. An Overview of Coumarin as a Versatile and Readily Accessible Scaffold with Broad-Ranging Biological Activities. Int J Mol Sci. 2020;21:4618. [DOI] [PubMed] [PMC]
- 234. Sharifi-Rad J, Cruz-Martins N, López-Jornet P, Lopez EP, Harun N, Yeskaliyeva B, et al. Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms. Oxid Med Cell Longev. 2021;2021:6492346. [DOI] [PubMed] [PMC]
- 235. Diaz G, Miranda IL, Diaz MAN. Quinolines, Isoquinolines, Angustureine, and Congeneric Alkaloids Occurrence, Chemistry, and Biological Activity. In: Rao AV, Rao LG, editors. Phytochemicals Isolation, Characterisation and Role in Human Health. Rijeka: IntechOpen; 2015. [DOI]
- 236. Majc B, Sever T, Zarić M, Breznik B, Turk B, Lah TT. Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment. Biochim Biophys Acta Mol Cell Res. 2020;1867:118782. [DOI] [PubMed]
- 237. Schindler F, Zähner H. Metabolic products of microorganisms. 91. Tryptanthrin, a tryptophan derived antibiotic from *Candida lipolytica*. Arch Mikrobiol. 1971;79:187–203. German. [DOI] [PubMed]
- 238. Hosoe T, Nozawa K, Kawahara N, Fukushima K, Nishimura K, Miyaji M, et al. Isolation of a new potent cytotoxic pigment along with indigotin from the pathogenic basidiomycetous fungus *Schizophyllum commune*. Mycopathologia. 1999;146:9–12. [DOI] [PubMed]

- 239. Costa DCM, Azevedo MMB, Silva DOE, Romanos MTV, Souto-Padrón TCBS, Alviano CS, et al. *In vitro* anti-MRSA activity *of Couroupita guianensis* extract and its component Tryptanthrin. Nat Prod Res. 2017;31:2077–80. [DOI] [PubMed]
- 240. Muruganandam AV, Bhattacharya SK, Ghosal S. Indole and flavanoid constituents of *Wrightia tinctoria*, *W. tomentosa* and *W. coccinea*. Indian J Chem. 2000;39:125–31.
- 241. Honda G, Tabata M. Isolation of antifungal principle tryptanthrin, from Strobilanthes cusia O. Kuntze. Planta Med. 1979;36:85–6. [DOI] [PubMed]
- 242. Micallef MJ, Iwaki K, Ishihara T, Ushio S, Aga M, Kunikata T, et al. The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol. 2002;2:565–78. [DOI] [PubMed]
- 243. Heinemann C, Schliemann-Willers S, Oberthür C, Hamburger M, Elsner P. Prevention of experimentally induced irritant contact dermatitis by extracts of *Isatis tinctoria* compared to pure tryptanthrin and its impact on UVB-induced erythema. Planta Med. 2004;70:385–90. [DOI] [PubMed]
- 244. Kwon YW, Cheon SY, Park SY, Song J, Lee JH. Tryptanthrin Suppresses the Activation of the LPS-Treated BV2 Microglial Cell Line via Nrf2/HO-1 Antioxidant Signaling. Front Cell Neurosci. 2017;11: 18. [DOI] [PubMed] [PMC]
- 245. Obafemi CA, Adegbite OB, Fadare OA, Iwalewa EO, Omisore NO, Sanusi K, et al. Tryptanthrin from microwave-assisted reduction of isatin using solid-state-supported sodium borohydride: DFT calculations, molecular docking and evaluation of its analgesic and anti-inflammatory activity. Heliyon. 2021;7:e05756. [DOI] [PubMed] [PMC]
- 246. Kirpotina LN, Schepetkin IA, Hammaker D, Kuhs A, Khlebnikov AI, Quinn MT. Therapeutic Effects of Tryptanthrin and Tryptanthrin-6-Oxime in Models of Rheumatoid Arthritis. Front Pharmacol. 2020; 11:1145. [DOI] [PubMed] [PMC]
- 247. Kutlu Z, Halici Z, Gedikli S, Diyarbakir B, Civelek MS. A Lead Target Molecule for Excisional Wound Healing: Trypthantrin Compound. Iran J Pharm Res. 2022;21:e127665. [DOI] [PubMed] [PMC]
- 248. Cheng HM, Kuo YZ, Chang CY, Chang CH, Fang WY, Chang CN, et al. The anti-TH17 polarization effect of *Indigo naturalis* and tryptanthrin by differentially inhibiting cytokine expression. J Ethnopharmacol. 2020;255:112760. [DOI] [PubMed]
- 249. Lee S, Kim DC, Baek HY, Lee KD, Kim YC, Oh H. Anti-neuroinflammatory effects of tryptanthrin from *Polygonum tinctorium* Lour. in lipopolysaccharide-stimulated BV2 microglial cells. Arch Pharm Res. 2018;41:419–30. [DOI] [PubMed]
- 250. Jung EH, Jung JY, Ko HL, Kim JK, Park SM, Jung DH, et al. Tryptanthrin prevents oxidative stress-mediated apoptosis through AMP-activated protein kinase-dependent p38 mitogen-activated protein kinase activation. Arch Pharm Res. 2017;40:1071–86. [DOI] [PubMed]
- 251. Han NR, Kim HM, Jeong HJ. Tryptanthrin reduces mast cell proliferation promoted by TSLP through modulation of MDM2 and p53. Biomed Pharmacother. 2016;79:71–7. [DOI] [PubMed]
- 252. Pergola C, Jazzar B, Rossi A, Northoff H, Hamburger M, Sautebin L, et al. On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy *in vivo*. Br J Pharmacol. 2012;165:765–76. [DOI] [PubMed] [PMC]
- 253. Gao JY, Chang CS, Lien JC, Chen TW, Hu JL, Weng JR. Synthetic Tryptanthrin Derivatives Induce Cell Cycle Arrest and Apoptosis via Akt and MAPKs in Human Hepatocellular Carcinoma Cells. Biomedicines. 2021;9:1527. [DOI] [PubMed] [PMC]
- 254. Zeng Q, Luo C, Cho J, Lai D, Shen X, Zhang X, et al. Tryptanthrin exerts anti-breast cancer effects both *in vitro* and *in vivo* through modulating the inflammatory tumor microenvironment. Acta Pharm. 2021;71:245–66. [DOI] [PubMed]
- 255. Jun KY, Park SE, Liang JL, Jahng Y, Kwon Y. Benzo[*b*]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells. ChemMedChem. 2015;10:827–35. [DOI] [PubMed]

- 256. Yang S, Li X, Hu F, Li Y, Yang Y, Yan J, et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013;56:8321–31. [DOI] [PubMed]
- 257. Kimoto T, Hino K, Koya-Miyata S, Yamamoto Y, Takeuchi M, Nishizaki Y, et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of *Polygonum tinctorium* Lour. Pathol Int. 2001;51:315–25. [DOI] [PubMed]
- 258. Shabna A, Antony J, Vijayakurup V, Saikia M, Liju VB, Retnakumari AP, et al. Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis. Cell Mol Life Sci. 2022;79:478. [DOI] [PubMed] [PMC]
- 259. Shankar G M, Alex VV, Nisthul A A, Bava SV, Sundaram S, Retnakumari AP, et al. Pre-clinical evidences for the efficacy of tryptanthrin as a potent suppressor of skin cancer. Cell Prolif. 2020;53: e12710. [DOI] [PubMed] [PMC]
- 260. Liang D, Li Q, Du L, Dou G. Pharmacological Effects and Clinical Prospects of Cepharanthine. Molecules. 2022;27:8933. [DOI] [PubMed] [PMC]
- 261. Cierluk K, Szlasa W, Rossowska J, Tarek M, Szewczyk A, Saczko J, et al. Cepharanthine induces ROS stress in glioma and neuronal cells via modulation of VDAC permeability. Saudi Pharm J. 2020;28: 1364–73. [DOI] [PubMed] [PMC]
- 262. Liu K, Hong B, Wang S, Lou F, You Y, Hu R, et al. Pharmacological Activity of Cepharanthine. Molecules. 2023;28:5019. [DOI] [PubMed] [PMC]
- 263. Zhao Y, Fu T, Meng G, Qiao F, Hou Y, Liu Y, et al. Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line. Anticancer Agents Med Chem. 2020;20:2293–303. [DOI] [PubMed]
- 264. Wang HG, Zhang MN, Wen X, He L, Zhang MH, Zhang JL, et al. Cepharanthine ameliorates dextran sulphate sodium-induced colitis through modulating gut microbiota. Microb Biotechnol. 2022;15: 2208–22. [DOI] [PubMed] [PMC]
- 265. Zhang MN, Xie R, Wang HG, Wen X, Wang JY, He L, et al. Cepharanthine Alleviates DSS-Induced Ulcerative Colitis via Regulating Aconitate Decarboxylase 1 Expression and Macrophage Infiltration. Molecules. 2023;28:1060. [DOI] [PubMed] [PMC]
- 266. Detpichai Y. Anticancer activity of cepharanthine on non-small cell lung cancer cells [dissertation]. Chulalongkorn University; 2020. [DOI]
- 267. Su GF, Huang ZX, Huang DL, Chen PX, Wang Y, Wang YF. Cepharanthine hydrochloride inhibits the Wnt/β-catenin/Hedgehog signaling axis in liver cancer. Oncol Rep. 2022;47:83. [DOI] [PubMed] [PMC]
- 268. Liu C, Wang R, Jiao X, Zhang J, Zhang C, Wang Z. Oxysophocarpine suppresses TRAF6 level to ameliorate oxidative stress and inflammatory factors secretion in mice with dextran sulphate sodium (DSS) induced-ulcerative colitis. Microb Pathog. 2023;182:106244. [DOI] [PubMed]
- 269. Zhi W, Jiang S, Xu Z, An Y, Chen J, Li Y, et al. Oxysophocarpine inhibits airway inflammation and mucus hypersecretion through JNK/AP-1 pathway in vivo and in vitro. Fitoterapia. 2022;162: 105278. [DOI] [PubMed]
- 270. Zhang L, Liu W, Zhang R, Wang Z, Shen Z, Chen X, et al. Pharmacokinetic study of matrine, oxymatrine and oxysophocarpine in rat plasma after oral administration of *Sophora flavescens* Ait. extract by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2008;47:892–8. [DOI] [PubMed]
- 271. Zhu QL, Li YX, Zhou R, Ma NT, Chang RY, Wang TF, et al. Neuroprotective effects of oxysophocarpine on neonatal rat primary cultured hippocampal neurons injured by oxygen-glucose deprivation and reperfusion. Pharm Biol. 2014;52:1052–9. [DOI] [PubMed]
- 272. Yang D, Chen F, Gu Z, Lü L, Ding G, Peng Z, et al. Oxysophocarpine reduces oxidative stress and inflammation in tuberculosis-infected neutrophils and mouse lungs. Int J Clin Exp Pathol. 2020;13: 1506–17. [PubMed] [PMC]

- 273. Zhao P, Chang RY, Liu N, Wang J, Zhou R, Qi X, et al. Neuroprotective Effect of Oxysophocarpine by Modulation of MAPK Pathway in Rat Hippocampal Neurons Subject to Oxygen-Glucose Deprivation and Reperfusion. Cell Mol Neurobiol. 2018;38:529–40. [DOI] [PubMed]
- 274. Cao X, He Q. Anti-Tumor Activities of Bioactive Phytochemicals in *Sophora flavescens* for Breast Cancer. Cancer Manag Res. 2020;12:1457–67. [DOI] [PubMed] [PMC]
- 275. Ponticelli M, Bellone ML, Parisi V, Iannuzzi A, Braca A, de Tommasi N, et al. Specialized metabolites from plants as a source of new multi-target antiviral drugs: a systematic review. Phytochem Rev. 2023;22:615–93. [DOI] [PubMed] [PMC]
- 276. Wang FL, Wang H, Wang JH, Wang DX, Gao Y, Yang B, et al. Analgesic and Anti-Inflammatory Activities of Sophocarpine from *Sophora viciifolia* Hance. Biomed Res Int. 2021;2021:8893563. [DOI] [PubMed] [PMC]
- 277. Lu Y, Lou J, Liu X, Wang S. Oxysophocarpine reduces oxygen-glucose deprivation-induced microglial activation and injury. Am J Transl Res. 2017;9:2266–75. [PubMed] [PMC]
- 278. Wang J, Wei W, Tang Q, Lu L, Luo Z, Li W, et al. Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression. Cancer Med. 2020;9:7125–36. [DOI] [PubMed] [PMC]
- 279. Liu R, Peng J, Wang H, Li L, Wen X, Tan Y, et al. Oxysophocarpine Retards the Growth and Metastasis of Oral Squamous Cell Carcinoma by Targeting the Nrf2/HO-1 Axis. Cell Physiol Biochem. 2018;49: 1717–33. [DOI] [PubMed]
- 280. Tillhon M, Guamán Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84:1260–7. [DOI] [PubMed]
- 281. Ahmed T, Gilani AU, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. Berberine and neurodegeneration: A review of literature. Pharmacol Rep. 2015;67:970–9. [DOI] [PubMed]
- 282. Imenshahidi M, Hosseinzadeh H. *Berberis Vulgaris* and Berberine: An Update Review. Phytother Res. 2016;30:1745–64. [DOI] [PubMed]
- 283. Solanki R, Parmar B, Jadav M, Pooja D, Kulhari H, Patel S. Berberine encapsulated phenylboronic acid-conjugated pullulan nanoparticles: Synthesis, characterization and anticancer activity validated in A431 skin cancer cells and 3D spheroids. Int J Biol Macromol. 2024;273:132737. [DOI] [PubMed]
- 284. Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from *Evodia rutaecarpa*. Molecules. 2009;14: 1852–9. [DOI] [PubMed] [PMC]
- 285. Sun Q, Xie L, Song J, Li X. Evodiamine: A review of its pharmacology, toxicity, pharmacokinetics and preparation researches. J Ethnopharmacol. 2020;262:113164. [DOI] [PubMed]
- 286. Solanki R, Patel S. Evodiamine and its nano-based approaches for enhanced cancer therapy: recent advances and challenges. J Sci Food Agric. 2024;104:8430–44. [DOI] [PubMed]
- 287. Yu H, Jin H, Gong W, Wang Z, Liang H. Pharmacological actions of multi-target-directed evodiamine. Molecules. 2013;18:1826–43. [DOI] [PubMed] [PMC]
- 288. Panda M, Tripathi SK, Zengin G, Biswal BK. Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers. Cell Biol Toxicol. 2023;39:1–31. [DOI] [PubMed]
- 289. Miękus N, Marszałek K, Podlacha M, Iqbal A, Puchalski C, Świergiel AH. Health Benefits of Plant-Derived Sulfur Compounds, Glucosinolates, and Organosulfur Compounds. Molecules. 2020;25:3804. [DOI] [PubMed] [PMC]
- 290. Ruhee RT, Roberts LA, Ma S, Suzuki K. Organosulfur Compounds: A Review of Their Anti-inflammatory Effects in Human Health. Front Nutr. 2020;7:64. [DOI] [PubMed] [PMC]
- 291. Al-Ishaq RK, Overy AJ, Büsselberg D. Phytochemicals and Gastrointestinal Cancer: Cellular Mechanisms and Effects to Change Cancer Progression. Biomolecules. 2020;10:105. [DOI] [PubMed] [PMC]

- 292. Fahimirad S, Hatami M. Chapter 12 Nanocarrier-Based Antimicrobial Phytochemicals. In: Ghorbanpour M, Wani SH, editors. Advances in Phytonanotechnology. Academic Press; 2019. pp. 299–314. [DOI]
- 293. Bayat Mokhtari R, Baluch N, Homayouni TS, Morgatskaya E, Kumar S, Kazemi P, et al. The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review. J Cell Commun Signal. 2018;12:91–101. [DOI] [PubMed] [PMC]
- 294. Lara-Espinoza C, Carvajal-Millán E, Balandrán-Quintana R, López-Franco Y, Rascón-Chu A. Pectin and Pectin-Based Composite Materials: Beyond Food Texture. Molecules. 2018;23:942. [DOI] [PubMed] [PMC]
- 295. Ornelas AC, Ferguson S, DePlaza M, Adekunle T, Basha R. Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment. Onco Ther. 2022;9:43–55. [DOI] [PubMed] [PMC]
- 296. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344:1788–91. [DOI] [PubMed] [PMC]
- 297. Perez-Ternero C, Werner CM, Nickel AG, Herrera MD, Motilva MJ, Böhm M, et al. Ferulic acid, a bioactive component of rice bran, improves oxidative stress and mitochondrial biogenesis and dynamics in mice and in human mononuclear cells. J Nutr Biochem. 2017;48:51–61. [DOI] [PubMed]
- 298. Saji N, Francis N, Schwarz LJ, Blanchard CL, Santhakumar AB. Rice Bran Derived Bioactive Compounds Modulate Risk Factors of Cardiovascular Disease and Type 2 Diabetes Mellitus: An Updated Review. Nutrients. 2019;11:2736. [DOI] [PubMed] [PMC]
- 299. Dahiya R, Dahiya S, Fuloria NK, Kumar S, Mourya R, Chennupati SV, et al. Natural Bioactive Thiazole-Based Peptides from Marine Resources: Structural and Pharmacological Aspects. Mar Drugs. 2020; 18:329. [DOI] [PubMed] [PMC]
- 300. Kumar P, Kumar S, Kumar R. *In vitro* study of plant extract from *Chenopodium album* that inhibits a key enzyme in diabetes and its role in diabetic oxidative stress. Pharm Sin. 2015;6:48–61.
- 301. Saharan R, Pal P, Sachdeva S, Kumar S, Singh R. Garlic the Wonder Adjuvant in Medicinal Field. Exp Appl Biomed Res (EABR). 2023;24:159–68. [DOI]
- 302. Chavda VP, Nalla LV, Balar P, Bezbaruah R, Apostolopoulos V, Singla RK, et al. Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer. Cancers (Basel). 2023;15:1023. [DOI] [PubMed] [PMC]
- 303. Nasim N, Sandeep IS, Mohanty S. Plant-derived natural products for drug discovery: current approaches and prospects. Nucleus (Calcutta). 2022;65:399–411. [DOI] [PubMed] [PMC]
- 304. Solanki R, Jodha B, Prabina KE, Aggarwal N, Patel S. Recent advances in phytochemical based nanodrug delivery systems to combat breast cancer: A review. J Drug Delivery Sci Technol. 2022;77: 103832. [DOI]
- 305. Subramanian AP, Jaganathan SK, Manikandan A, Pandiaraj KN, N G, Supriyanto E. Recent trends in nano-based drug delivery systems for efficient delivery of phytochemicals in chemotherapy. RSC Adv. 2016;6:48294–314. [DOI]